<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="lead">
            <roleset id="lead.01" name="resulted&#x0A;" wordnet="3">
                <roles>
                    <role n="0" descr="factors&#x0A;" />
                    <role n="1" descr="result&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations that lead to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations that led to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations which lead to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations which led to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription can lead us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription leads us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription led us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription will lead us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D can lead to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D has led to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D is able to lead to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D may lead to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Crl stimulates the activity of sigma (S) lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Crl stimulates the activity of sigma (S) led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Disruption of the SNU246 gene in yeast is lethal and can lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Disruption of the SNU246 gene in yeast was lethal and could lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Disruption of the SNU246 gene in yeast was lethal and led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Disruption of the SNU246 gene in yeast was lethal and might lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction could lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction had led to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction was able to lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that DNA (nCaRE)-ref1 interaction is able to lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that DNA (nCaRE)-ref1 interaction leads to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Genetic deficiency of GM2 activator can lead to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Genetic deficiency of GM2 activator has led to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Genetic deficiency of GM2 activator is leading to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Genetic deficiency of GM2 activator led to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% decrease in expression when cells are cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite has led to a 45% decrease in expression when cells were cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression when cells are cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% decrease in expression when cells were cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite will lead to a 45% decrease in expression when cells are going to be cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, can lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, could lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, is able to lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, which led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivated the 5 cleavage event of splicing and can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivated the 5 cleavage event of splicing and has led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivated the 5 cleavage event of splicing and led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivated the 5 cleavage event of splicing and will lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivates the 5 cleavage event of splicing and is able to lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>The loss of TreR function can lead to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>The loss of TreR function has led to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>The loss of TreR function leads to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>The loss of TreR function will lead to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>The mutations identified include: two frameshifts and a splice site mutation that lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>The mutations identified include: two frameshifts and a splice site mutation which have led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>The mutations identified include: two frameshifts and a splice site mutation which lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>The mutations identified include: two frameshifts and a splice site mutation which led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>The splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>The splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>The splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>The splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>These data suggest that phosphorylation of the MuSK NPXY site can lead to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>These data suggest that phosphorylation of the MuSK NPXY site has led to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>These data suggest that phosphorylation of the MuSK NPXY site will lead to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>These data suggested that phosphorylation of the MuSK NPXY site led to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>These data suggested that phosphorylation of the MuSK NPXY site was able to lead to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>These results suggest that the distinct amino termini can lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>These results suggest that the distinct amino termini is able to lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>These results suggest that the distinct amino termini may lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>These results suggested that the distinct amino termini has led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment leading to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment that leads to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment which has led to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment which leads to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment which led to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>This can lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>This has led to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>This is leading to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>This may lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which can lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>This splice mutation in 5 end of intron 5 might has led to abnormal splice in exon 5 and exon 6 and has brought about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>This splice mutation in 5 end of intron 5 might is leading to abnormal splice in exon 5 and exon 6 and bringing about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>This splice mutation in 5 end of intron 5 might led to abnormal splice in exon 5 and exon 6 and brought about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>This that leads to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 that leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 that led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 which can lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 which has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>This, in turn, has led to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>This, in turn, is able to lead to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>This, in turn, is leading to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>This, in turn, led to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>This, in turn, will lead to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, can lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, has led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, is able to lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, leads to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, will lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>We also studied in detail a complex splice site mutation, 3332dupl8bp, which leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>We also studied in detail a complex splice site mutation, 3332dupl8bp, which led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>We also studied in detail a complex splice site mutation, 3332dupl8bp, which was found to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>We also study in detail a complex splice site mutation, 3332dupl8bp, leading to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>We also study in detail a complex splice site mutation, 3332dupl8bp, which is believed to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase is led to by Crl stimulates the activity of sigma (S).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase was led to by Crl stimulates the activity of sigma (S).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leads to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>These data suggest that phosphorylation of the MuSK NPXY site leads to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EMBO" no="4">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment, which led to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EMBO" no="5">
                    <text>This, in turn, leads to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="GREC" no="1">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription has led us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="GREC" no="2">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction led to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="GREC" no="3">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression when cells were cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="GREC" no="4">
                    <text>It has been shown that Crl stimulates the activity of sigma (S), leading to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="GREC" no="5">
                    <text>The loss of TreR function led to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="GREC" no="6">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations leading to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>Disruption of the SNU246 gene in yeast is lethal and leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="MEDLINE" no="3">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="MEDLINE" no="4">
                    <text>Genetic deficiency of GM2 activator leads to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="MEDLINE" no="5">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivates the 5 cleavage event of splicing and leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="MEDLINE" no="6">
                    <text>The mutations identified include: two frameshifts and a splice site mutation leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="MEDLINE" no="7">
                    <text>The splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="MEDLINE" no="8">
                    <text>These results suggest that the distinct amino termini lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="MEDLINE" no="9">
                    <text>This leads to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="MEDLINE" no="10">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that is detectably expressed, leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="MEDLINE" no="11">
                    <text>This splice mutation in 5 end of intron 5 might lead to abnormal splice in exon 5 and exon 6 and bring about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="MEDLINE" no="12">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383, which leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="MEDLINE" no="13">
                    <text>We also studied in detail a complex splice site mutation, 3332dupl8bp, which was shown to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>7 missense mutations, 2 mutations can lead to frameshift (Figure 3A).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>7 missense mutations, 2 mutations can lead to frameshift, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>7 missense mutations, 2 mutations can lead to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>7 missense mutations, 2 mutations can lead us to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>7 missense mutations, 2 mutations has led to frameshift (Figure 3A).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>7 missense mutations, 2 mutations has led to frameshift, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>7 missense mutations, 2 mutations has led to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>7 missense mutations, 2 mutations has led us to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>7 missense mutations, 2 mutations is able to lead to frameshift (Figure 3A).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>7 missense mutations, 2 mutations is leading to frameshift, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>7 missense mutations, 2 mutations is leading to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>7 missense mutations, 2 mutations lead to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>7 missense mutations, 2 mutations leads to frameshift (Figure 3A).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>7 missense mutations, 2 mutations leads to frameshift, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>7 missense mutations, 2 mutations leads to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>7 missense mutations, 2 mutations leads us to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>7 missense mutations, 2 mutations led to frameshift (Figure 3A).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>7 missense mutations, 2 mutations led to frameshift, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>7 missense mutations, 2 mutations led to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>7 missense mutations, 2 mutations led us to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>7 missense mutations, 2 mutations may lead to frameshift (Figure 3A).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>7 missense mutations, 2 mutations may lead to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>7 missense mutations, 2 mutations that leads to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>7 missense mutations, 2 mutations will lead us to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>7 missense mutations, 2 mutations, but not a wild-type strain, led to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>7 missense mutations, 2 mutations, in turn, has led to frameshift independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>7 missense mutations, 2 mutations, in turn, is able to lead to frameshift independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>7 missense mutations, 2 mutations, in turn, is leading to frameshift independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>7 missense mutations, 2 mutations, in turn, leads to frameshift independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>7 missense mutations, 2 mutations, in turn, led to frameshift independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>7 missense mutations, 2 mutations, in turn, will lead to frameshift independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Closer examination of the putative signal transduction pathway modulating htrA transcription leading to the identification of two new genes, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Closer examination of the putative signal transduction pathway modulating htrA transcription that lead to the identification of two new genes, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Closer examination of the putative signal transduction pathway modulating htrA transcription that led to the identification of two new genes, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Closer examination of the putative signal transduction pathway modulating htrA transcription which lead to the identification of two new genes, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Closer examination of the putative signal transduction pathway modulating htrA transcription which led to the identification of two new genes, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leading to a synergistic 40-to 50-fold activation of the ANF promoter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D that lead to a synergistic 40-to 50-fold activation of the ANF promoter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D that led to a synergistic 40-to 50-fold activation of the ANF promoter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D which lead to a synergistic 40-to 50-fold activation of the ANF promoter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D which led to a synergistic 40-to 50-fold activation of the ANF promoter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Crl stimulates the activity of sigma (S) leading to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Crl stimulates the activity of sigma (S) that lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Crl stimulates the activity of sigma (S) that led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Crl stimulates the activity of sigma (S) which lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Crl stimulates the activity of sigma (S) which led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (DNA (nCaRE)-ref1 interaction leading to C2+e-mediated transcriptional suppression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (DNA (nCaRE)-ref1 interaction that lead to C2+e-mediated transcriptional suppression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (DNA (nCaRE)-ref1 interaction that led to C2+e-mediated transcriptional suppression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (DNA (nCaRE)-ref1 interaction which lead to C2+e-mediated transcriptional suppression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (DNA (nCaRE)-ref1 interaction which led to C2+e-mediated transcriptional suppression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Genetic deficiency of GM2 activator leading to a neurological disorder, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Genetic deficiency of GM2 activator that lead to a neurological disorder, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Genetic deficiency of GM2 activator that led to a neurological disorder, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Genetic deficiency of GM2 activator which lead to a neurological disorder, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Genetic deficiency of GM2 activator which led to a neurological disorder, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This leading to a substantial diversity of nebulin and nebulette isoforms, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This leading to synergistic activation of the ANF and other MEF2 target promoters, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This that lead to a substantial diversity of nebulin and nebulette isoforms, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This that lead to synergistic activation of the ANF and other MEF2 target promoters, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This that led to a substantial diversity of nebulin and nebulette isoforms, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This that led to synergistic activation of the ANF and other MEF2 target promoters, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This which lead to a substantial diversity of nebulin and nebulette isoforms, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This which lead to synergistic activation of the ANF and other MEF2 target promoters, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This which led to a substantial diversity of nebulin and nebulette isoforms, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This which led to synergistic activation of the ANF and other MEF2 target promoters, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Transduction of the marA region from a Mar strain leading to loss of OmpF, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Transduction of the marA region from a Mar strain that lead to loss of OmpF, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Transduction of the marA region from a Mar strain that led to loss of OmpF, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Transduction of the marA region from a Mar strain which lead to loss of OmpF, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Transduction of the marA region from a Mar strain which led to loss of OmpF, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation (GTC----ATC) at codon 383 leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation (GTC----ATC) at codon 383 that lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation (GTC----ATC) at codon 383 that led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation (GTC----ATC) at codon 383 which lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation (GTC----ATC) at codon 383 which led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (phosphorylation of the MuSK NPXY site leading to recruitment of a phosphotyrosine-binding domain-containing protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (phosphorylation of the MuSK NPXY site that lead to recruitment of a phosphotyrosine-binding domain-containing protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (phosphorylation of the MuSK NPXY site that led to recruitment of a phosphotyrosine-binding domain-containing protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (phosphorylation of the MuSK NPXY site which lead to recruitment of a phosphotyrosine-binding domain-containing protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (phosphorylation of the MuSK NPXY site which led to recruitment of a phosphotyrosine-binding domain-containing protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the sequence selection experiment leading to the identification of the BRE, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the sequence selection experiment that lead to the identification of the BRE, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the sequence selection experiment that led to the identification of the BRE, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the sequence selection experiment which lead to the identification of the BRE, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the sequence selection experiment which led to the identification of the BRE, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>C2+e-mediated transcriptional suppression is led to by DNA (nCaRE)-ref1 interaction.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>C2+e-mediated transcriptional suppression was led to by DNA (nCaRE)-ref1 interaction.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription can lead to the identification of two new genes (Figure 3A).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription can lead to the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription can lead to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription has led to the identification of two new genes (Figure 3A).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription has led to the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription has led to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription is able to lead to the identification of two new genes (Figure 3A).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription is leading to the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription is leading to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription lead to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription leads to the identification of two new genes (Figure 3A).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription leads to the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription led to the identification of two new genes (Figure 3A).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription led to the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription led to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription may lead to the identification of two new genes (Figure 3A).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription may lead to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription that leads to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription, but not a wild-type strain, led to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription, in turn, has led to the identification of two new genes independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription, in turn, is able to lead to the identification of two new genes independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription, in turn, is leading to the identification of two new genes independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription, in turn, leads to the identification of two new genes independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription, in turn, led to the identification of two new genes independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription, in turn, will lead to the identification of two new genes independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D can lead to a synergistic 40-to 50-fold activation of the ANF promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D can lead to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D can lead us to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D has led to a synergistic 40-to 50-fold activation of the ANF promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D has led to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D has led us to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D is leading to a synergistic 40-to 50-fold activation of the ANF promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D is leading to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D lead to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leads to a synergistic 40-to 50-fold activation of the ANF promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leads to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leads us to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a synergistic 40-to 50-fold activation of the ANF promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D led us to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D may lead to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D that leads to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D will lead us to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, but not a wild-type strain, led to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, in turn, has led to a synergistic 40-to 50-fold activation of the ANF promoter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, in turn, is able to lead to a synergistic 40-to 50-fold activation of the ANF promoter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, in turn, is leading to a synergistic 40-to 50-fold activation of the ANF promoter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, in turn, leads to a synergistic 40-to 50-fold activation of the ANF promoter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, in turn, led to a synergistic 40-to 50-fold activation of the ANF promoter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, in turn, will lead to a synergistic 40-to 50-fold activation of the ANF promoter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Crl stimulates the activity of sigma (S) can lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Figure 3A).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Crl stimulates the activity of sigma (S) can lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Crl stimulates the activity of sigma (S) can lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Crl stimulates the activity of sigma (S) can lead us to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Crl stimulates the activity of sigma (S) has led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Figure 3A).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Crl stimulates the activity of sigma (S) has led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Crl stimulates the activity of sigma (S) has led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Crl stimulates the activity of sigma (S) has led us to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Crl stimulates the activity of sigma (S) is able to lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Figure 3A).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Crl stimulates the activity of sigma (S) is leading to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Crl stimulates the activity of sigma (S) is leading to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Crl stimulates the activity of sigma (S) leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Figure 3A).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Crl stimulates the activity of sigma (S) leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Crl stimulates the activity of sigma (S) leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Crl stimulates the activity of sigma (S) leads us to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Crl stimulates the activity of sigma (S) led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Figure 3A).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Crl stimulates the activity of sigma (S) led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Crl stimulates the activity of sigma (S) led us to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Crl stimulates the activity of sigma (S) may lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Figure 3A).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Crl stimulates the activity of sigma (S) may lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Crl stimulates the activity of sigma (S) that leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Crl stimulates the activity of sigma (S) will lead us to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Crl stimulates the activity of sigma (S), but not a wild-type strain, led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Crl stimulates the activity of sigma (S), in turn, has led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Crl stimulates the activity of sigma (S), in turn, is able to lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Crl stimulates the activity of sigma (S), in turn, is leading to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Crl stimulates the activity of sigma (S), in turn, leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Crl stimulates the activity of sigma (S), in turn, led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Crl stimulates the activity of sigma (S), in turn, will lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>DNA (nCaRE)-ref1 interaction can lead to C2+e-mediated transcriptional suppression (Figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>DNA (nCaRE)-ref1 interaction can lead to C2+e-mediated transcriptional suppression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>DNA (nCaRE)-ref1 interaction can lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>DNA (nCaRE)-ref1 interaction can lead us to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>DNA (nCaRE)-ref1 interaction has led to C2+e-mediated transcriptional suppression (Figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>DNA (nCaRE)-ref1 interaction has led to C2+e-mediated transcriptional suppression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>DNA (nCaRE)-ref1 interaction has led to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>DNA (nCaRE)-ref1 interaction has led us to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>DNA (nCaRE)-ref1 interaction is able to lead to C2+e-mediated transcriptional suppression (Figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>DNA (nCaRE)-ref1 interaction is leading to C2+e-mediated transcriptional suppression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>DNA (nCaRE)-ref1 interaction is leading to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>DNA (nCaRE)-ref1 interaction lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>DNA (nCaRE)-ref1 interaction leads to C2+e-mediated transcriptional suppression (Figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>DNA (nCaRE)-ref1 interaction leads to C2+e-mediated transcriptional suppression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>DNA (nCaRE)-ref1 interaction leads to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>DNA (nCaRE)-ref1 interaction leads us to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>DNA (nCaRE)-ref1 interaction led to C2+e-mediated transcriptional suppression (Figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>DNA (nCaRE)-ref1 interaction led to C2+e-mediated transcriptional suppression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>DNA (nCaRE)-ref1 interaction led to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>DNA (nCaRE)-ref1 interaction led us to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>DNA (nCaRE)-ref1 interaction may lead to C2+e-mediated transcriptional suppression (Figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>DNA (nCaRE)-ref1 interaction may lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>DNA (nCaRE)-ref1 interaction that leads to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>DNA (nCaRE)-ref1 interaction will lead us to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>DNA (nCaRE)-ref1 interaction, but not a wild-type strain, led to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>DNA (nCaRE)-ref1 interaction, in turn, has led to C2+e-mediated transcriptional suppression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>DNA (nCaRE)-ref1 interaction, in turn, is able to lead to C2+e-mediated transcriptional suppression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>DNA (nCaRE)-ref1 interaction, in turn, is leading to C2+e-mediated transcriptional suppression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>DNA (nCaRE)-ref1 interaction, in turn, leads to C2+e-mediated transcriptional suppression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>DNA (nCaRE)-ref1 interaction, in turn, led to C2+e-mediated transcriptional suppression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>DNA (nCaRE)-ref1 interaction, in turn, will lead to C2+e-mediated transcriptional suppression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that 7 missense mutations, 2 mutations could lead to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that 7 missense mutations, 2 mutations had led to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that 7 missense mutations, 2 mutations led to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that 7 missense mutations, 2 mutations was able to lead to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Closer examination of the putative signal transduction pathway modulating htrA transcription could lead to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Closer examination of the putative signal transduction pathway modulating htrA transcription had led to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Closer examination of the putative signal transduction pathway modulating htrA transcription led to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Closer examination of the putative signal transduction pathway modulating htrA transcription was able to lead to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D could lead to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D had led to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D was able to lead to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Crl stimulates the activity of sigma (S) could lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Crl stimulates the activity of sigma (S) had led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Crl stimulates the activity of sigma (S) led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Crl stimulates the activity of sigma (S) was able to lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Genetic deficiency of GM2 activator could lead to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Genetic deficiency of GM2 activator had led to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Genetic deficiency of GM2 activator led to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Genetic deficiency of GM2 activator was able to lead to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This could lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This could lead to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This had led to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This had led to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This led to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This led to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This was able to lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This was able to lead to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Transduction of the marA region from a Mar strain could lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Transduction of the marA region from a Mar strain had led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Transduction of the marA region from a Mar strain led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Transduction of the marA region from a Mar strain was able to lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a point mutation (GTC----ATC) at codon 383 could lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a point mutation (GTC----ATC) at codon 383 had led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a point mutation (GTC----ATC) at codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a point mutation (GTC----ATC) at codon 383 was able to lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that phosphorylation of the MuSK NPXY site could lead to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that phosphorylation of the MuSK NPXY site had led to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that phosphorylation of the MuSK NPXY site led to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that phosphorylation of the MuSK NPXY site was able to lead to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that the sequence selection experiment could lead to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that the sequence selection experiment had led to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that the sequence selection experiment led to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that the sequence selection experiment was able to lead to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that 7 missense mutations, 2 mutations is able to lead to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that 7 missense mutations, 2 mutations leads to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Closer examination of the putative signal transduction pathway modulating htrA transcription is able to lead to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Closer examination of the putative signal transduction pathway modulating htrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D is able to lead to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leads to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Crl stimulates the activity of sigma (S) is able to lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Crl stimulates the activity of sigma (S) leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Genetic deficiency of GM2 activator is able to lead to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Genetic deficiency of GM2 activator leads to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that This is able to lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that This is able to lead to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that This leads to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that This leads to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Transduction of the marA region from a Mar strain is able to lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Transduction of the marA region from a Mar strain leads to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that a point mutation (GTC----ATC) at codon 383 is able to lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that a point mutation (GTC----ATC) at codon 383 leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that phosphorylation of the MuSK NPXY site is able to lead to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that phosphorylation of the MuSK NPXY site leads to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that the sequence selection experiment is able to lead to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that the sequence selection experiment leads to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Genetic deficiency of GM2 activator can lead to a neurological disorder (Figure 3A).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Genetic deficiency of GM2 activator can lead to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Genetic deficiency of GM2 activator can lead us to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Genetic deficiency of GM2 activator has led to a neurological disorder (Figure 3A).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Genetic deficiency of GM2 activator has led to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Genetic deficiency of GM2 activator has led us to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Genetic deficiency of GM2 activator is able to lead to a neurological disorder (Figure 3A).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Genetic deficiency of GM2 activator is leading to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Genetic deficiency of GM2 activator lead to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Genetic deficiency of GM2 activator leads to a neurological disorder (Figure 3A).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Genetic deficiency of GM2 activator leads to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Genetic deficiency of GM2 activator leads us to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Genetic deficiency of GM2 activator led to a neurological disorder (Figure 3A).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Genetic deficiency of GM2 activator led to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Genetic deficiency of GM2 activator led us to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Genetic deficiency of GM2 activator may lead to a neurological disorder (Figure 3A).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Genetic deficiency of GM2 activator may lead to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Genetic deficiency of GM2 activator that leads to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Genetic deficiency of GM2 activator will lead us to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Genetic deficiency of GM2 activator, but not a wild-type strain, led to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Genetic deficiency of GM2 activator, in turn, has led to a neurological disorder independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>Genetic deficiency of GM2 activator, in turn, is able to lead to a neurological disorder independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>Genetic deficiency of GM2 activator, in turn, is leading to a neurological disorder independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>Genetic deficiency of GM2 activator, in turn, leads to a neurological disorder independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>Genetic deficiency of GM2 activator, in turn, led to a neurological disorder independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>Genetic deficiency of GM2 activator, in turn, will lead to a neurological disorder independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>It has been shown that 7 missense mutations, 2 mutations, leading to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>It has been shown that Closer examination of the putative signal transduction pathway modulating htrA transcription, leading to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>It has been shown that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, leading to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>It has been shown that DNA (nCaRE)-ref1 interaction, leading to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>It has been shown that Genetic deficiency of GM2 activator, leading to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>It has been shown that This, leading to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>It has been shown that This, leading to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>It has been shown that Transduction of the marA region from a Mar strain, leading to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>It has been shown that a point mutation (GTC----ATC) at codon 383, leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>It has been shown that phosphorylation of the MuSK NPXY site, leading to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>It has been shown that the sequence selection experiment, leading to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>These data suggest that 7 missense mutations, 2 mutations can lead to frameshift that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>These data suggest that 7 missense mutations, 2 mutations has led to frameshift that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>These data suggest that 7 missense mutations, 2 mutations leads to frameshift that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>These data suggest that 7 missense mutations, 2 mutations will lead to frameshift that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>These data suggest that Closer examination of the putative signal transduction pathway modulating htrA transcription can lead to the identification of two new genes that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>These data suggest that Closer examination of the putative signal transduction pathway modulating htrA transcription has led to the identification of two new genes that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>These data suggest that Closer examination of the putative signal transduction pathway modulating htrA transcription leads to the identification of two new genes that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>These data suggest that Closer examination of the putative signal transduction pathway modulating htrA transcription will lead to the identification of two new genes that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>These data suggest that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D can lead to a synergistic 40-to 50-fold activation of the ANF promoter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>These data suggest that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D has led to a synergistic 40-to 50-fold activation of the ANF promoter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>These data suggest that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leads to a synergistic 40-to 50-fold activation of the ANF promoter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>These data suggest that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D will lead to a synergistic 40-to 50-fold activation of the ANF promoter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>These data suggest that Crl stimulates the activity of sigma (S) can lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>These data suggest that Crl stimulates the activity of sigma (S) has led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>These data suggest that Crl stimulates the activity of sigma (S) leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>These data suggest that Crl stimulates the activity of sigma (S) will lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>These data suggest that DNA (nCaRE)-ref1 interaction can lead to C2+e-mediated transcriptional suppression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>These data suggest that DNA (nCaRE)-ref1 interaction has led to C2+e-mediated transcriptional suppression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>These data suggest that DNA (nCaRE)-ref1 interaction leads to C2+e-mediated transcriptional suppression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>These data suggest that DNA (nCaRE)-ref1 interaction will lead to C2+e-mediated transcriptional suppression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>These data suggest that Genetic deficiency of GM2 activator can lead to a neurological disorder that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>These data suggest that Genetic deficiency of GM2 activator has led to a neurological disorder that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>These data suggest that Genetic deficiency of GM2 activator leads to a neurological disorder that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>These data suggest that Genetic deficiency of GM2 activator will lead to a neurological disorder that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>These data suggest that This can lead to a substantial diversity of nebulin and nebulette isoforms that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>These data suggest that This can lead to synergistic activation of the ANF and other MEF2 target promoters that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>These data suggest that This has led to a substantial diversity of nebulin and nebulette isoforms that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>These data suggest that This has led to synergistic activation of the ANF and other MEF2 target promoters that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>These data suggest that This leads to a substantial diversity of nebulin and nebulette isoforms that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>These data suggest that This leads to synergistic activation of the ANF and other MEF2 target promoters that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>These data suggest that This will lead to a substantial diversity of nebulin and nebulette isoforms that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>These data suggest that This will lead to synergistic activation of the ANF and other MEF2 target promoters that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>These data suggest that Transduction of the marA region from a Mar strain can lead to loss of OmpF that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>These data suggest that Transduction of the marA region from a Mar strain has led to loss of OmpF that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>These data suggest that Transduction of the marA region from a Mar strain leads to loss of OmpF that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>These data suggest that Transduction of the marA region from a Mar strain will lead to loss of OmpF that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>These data suggest that a point mutation (GTC----ATC) at codon 383 can lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>These data suggest that a point mutation (GTC----ATC) at codon 383 has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>These data suggest that a point mutation (GTC----ATC) at codon 383 leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>These data suggest that a point mutation (GTC----ATC) at codon 383 will lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>These data suggest that the sequence selection experiment can lead to the identification of the BRE that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>These data suggest that the sequence selection experiment has led to the identification of the BRE that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>These data suggest that the sequence selection experiment leads to the identification of the BRE that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>These data suggest that the sequence selection experiment will lead to the identification of the BRE that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>These data suggested that 7 missense mutations, 2 mutations led to frameshift that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>These data suggested that 7 missense mutations, 2 mutations was able to lead to frameshift that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>These data suggested that Closer examination of the putative signal transduction pathway modulating htrA transcription led to the identification of two new genes that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>These data suggested that Closer examination of the putative signal transduction pathway modulating htrA transcription was able to lead to the identification of two new genes that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>These data suggested that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a synergistic 40-to 50-fold activation of the ANF promoter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>These data suggested that Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D was able to lead to a synergistic 40-to 50-fold activation of the ANF promoter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>These data suggested that Crl stimulates the activity of sigma (S) led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>These data suggested that Crl stimulates the activity of sigma (S) was able to lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>These data suggested that DNA (nCaRE)-ref1 interaction led to C2+e-mediated transcriptional suppression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>These data suggested that DNA (nCaRE)-ref1 interaction was able to lead to C2+e-mediated transcriptional suppression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>These data suggested that Genetic deficiency of GM2 activator led to a neurological disorder that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>These data suggested that Genetic deficiency of GM2 activator was able to lead to a neurological disorder that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>These data suggested that This led to a substantial diversity of nebulin and nebulette isoforms that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>These data suggested that This led to synergistic activation of the ANF and other MEF2 target promoters that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>These data suggested that This was able to lead to a substantial diversity of nebulin and nebulette isoforms that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>These data suggested that This was able to lead to synergistic activation of the ANF and other MEF2 target promoters that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>These data suggested that Transduction of the marA region from a Mar strain led to loss of OmpF that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>These data suggested that Transduction of the marA region from a Mar strain was able to lead to loss of OmpF that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>These data suggested that a point mutation (GTC----ATC) at codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>These data suggested that a point mutation (GTC----ATC) at codon 383 was able to lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>These data suggested that the sequence selection experiment led to the identification of the BRE that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>These data suggested that the sequence selection experiment was able to lead to the identification of the BRE that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>This G:C base pair is also the strongest determinant in 7 missense mutations, 2 mutations leading to frameshift (Lagrange et al., 1998).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>This G:C base pair is also the strongest determinant in 7 missense mutations, 2 mutations that leads to frameshift (Lagrange et al., 1998).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>This G:C base pair is also the strongest determinant in 7 missense mutations, 2 mutations which has led to frameshift (Lagrange et al., 1998).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>This G:C base pair is also the strongest determinant in 7 missense mutations, 2 mutations which leads to frameshift (Lagrange et al., 1998).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>This G:C base pair is also the strongest determinant in 7 missense mutations, 2 mutations which led to frameshift (Lagrange et al., 1998).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>This G:C base pair is also the strongest determinant in 7 missense mutations, 2 mutations, which led to frameshift (Lagrange et al., 1998).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>This G:C base pair is also the strongest determinant in Closer examination of the putative signal transduction pathway modulating htrA transcription leading to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>This G:C base pair is also the strongest determinant in Closer examination of the putative signal transduction pathway modulating htrA transcription that leads to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>This G:C base pair is also the strongest determinant in Closer examination of the putative signal transduction pathway modulating htrA transcription which has led to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>This G:C base pair is also the strongest determinant in Closer examination of the putative signal transduction pathway modulating htrA transcription which leads to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>This G:C base pair is also the strongest determinant in Closer examination of the putative signal transduction pathway modulating htrA transcription which led to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>This G:C base pair is also the strongest determinant in Closer examination of the putative signal transduction pathway modulating htrA transcription, which led to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>This G:C base pair is also the strongest determinant in Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leading to a synergistic 40-to 50-fold activation of the ANF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>This G:C base pair is also the strongest determinant in Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D that leads to a synergistic 40-to 50-fold activation of the ANF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>This G:C base pair is also the strongest determinant in Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D which has led to a synergistic 40-to 50-fold activation of the ANF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>This G:C base pair is also the strongest determinant in Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D which leads to a synergistic 40-to 50-fold activation of the ANF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>This G:C base pair is also the strongest determinant in Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D which led to a synergistic 40-to 50-fold activation of the ANF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>This G:C base pair is also the strongest determinant in Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, which led to a synergistic 40-to 50-fold activation of the ANF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>This G:C base pair is also the strongest determinant in Crl stimulates the activity of sigma (S) leading to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>This G:C base pair is also the strongest determinant in Crl stimulates the activity of sigma (S) that leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>This G:C base pair is also the strongest determinant in Crl stimulates the activity of sigma (S) which has led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>This G:C base pair is also the strongest determinant in Crl stimulates the activity of sigma (S) which leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>This G:C base pair is also the strongest determinant in Crl stimulates the activity of sigma (S) which led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>This G:C base pair is also the strongest determinant in Crl stimulates the activity of sigma (S), which led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>This G:C base pair is also the strongest determinant in DNA (nCaRE)-ref1 interaction leading to C2+e-mediated transcriptional suppression (Lagrange et al., 1998).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>This G:C base pair is also the strongest determinant in DNA (nCaRE)-ref1 interaction that leads to C2+e-mediated transcriptional suppression (Lagrange et al., 1998).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>This G:C base pair is also the strongest determinant in DNA (nCaRE)-ref1 interaction which has led to C2+e-mediated transcriptional suppression (Lagrange et al., 1998).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>This G:C base pair is also the strongest determinant in DNA (nCaRE)-ref1 interaction which leads to C2+e-mediated transcriptional suppression (Lagrange et al., 1998).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>This G:C base pair is also the strongest determinant in DNA (nCaRE)-ref1 interaction which led to C2+e-mediated transcriptional suppression (Lagrange et al., 1998).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>This G:C base pair is also the strongest determinant in DNA (nCaRE)-ref1 interaction, which led to C2+e-mediated transcriptional suppression (Lagrange et al., 1998).</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>This G:C base pair is also the strongest determinant in Genetic deficiency of GM2 activator leading to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>This G:C base pair is also the strongest determinant in Genetic deficiency of GM2 activator that leads to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>This G:C base pair is also the strongest determinant in Genetic deficiency of GM2 activator which has led to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>This G:C base pair is also the strongest determinant in Genetic deficiency of GM2 activator which leads to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>This G:C base pair is also the strongest determinant in Genetic deficiency of GM2 activator which led to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>This G:C base pair is also the strongest determinant in Genetic deficiency of GM2 activator, which led to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>This G:C base pair is also the strongest determinant in This leading to a substantial diversity of nebulin and nebulette isoforms (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>This G:C base pair is also the strongest determinant in This leading to synergistic activation of the ANF and other MEF2 target promoters (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>This G:C base pair is also the strongest determinant in This that leads to a substantial diversity of nebulin and nebulette isoforms (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>This G:C base pair is also the strongest determinant in This that leads to synergistic activation of the ANF and other MEF2 target promoters (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>This G:C base pair is also the strongest determinant in This which has led to a substantial diversity of nebulin and nebulette isoforms (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>This G:C base pair is also the strongest determinant in This which has led to synergistic activation of the ANF and other MEF2 target promoters (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>This G:C base pair is also the strongest determinant in This which leads to a substantial diversity of nebulin and nebulette isoforms (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>This G:C base pair is also the strongest determinant in This which leads to synergistic activation of the ANF and other MEF2 target promoters (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>This G:C base pair is also the strongest determinant in This which led to a substantial diversity of nebulin and nebulette isoforms (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>This G:C base pair is also the strongest determinant in This which led to synergistic activation of the ANF and other MEF2 target promoters (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>This G:C base pair is also the strongest determinant in This, which led to a substantial diversity of nebulin and nebulette isoforms (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>This G:C base pair is also the strongest determinant in This, which led to synergistic activation of the ANF and other MEF2 target promoters (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>This G:C base pair is also the strongest determinant in Transduction of the marA region from a Mar strain leading to loss of OmpF (Lagrange et al., 1998).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>This G:C base pair is also the strongest determinant in Transduction of the marA region from a Mar strain that leads to loss of OmpF (Lagrange et al., 1998).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>This G:C base pair is also the strongest determinant in Transduction of the marA region from a Mar strain which has led to loss of OmpF (Lagrange et al., 1998).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>This G:C base pair is also the strongest determinant in Transduction of the marA region from a Mar strain which leads to loss of OmpF (Lagrange et al., 1998).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>This G:C base pair is also the strongest determinant in Transduction of the marA region from a Mar strain which led to loss of OmpF (Lagrange et al., 1998).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>This G:C base pair is also the strongest determinant in Transduction of the marA region from a Mar strain, which led to loss of OmpF (Lagrange et al., 1998).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>This G:C base pair is also the strongest determinant in a point mutation (GTC----ATC) at codon 383 leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>This G:C base pair is also the strongest determinant in a point mutation (GTC----ATC) at codon 383 that leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>This G:C base pair is also the strongest determinant in a point mutation (GTC----ATC) at codon 383 which has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>This G:C base pair is also the strongest determinant in a point mutation (GTC----ATC) at codon 383 which leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>This G:C base pair is also the strongest determinant in a point mutation (GTC----ATC) at codon 383 which led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>This G:C base pair is also the strongest determinant in a point mutation (GTC----ATC) at codon 383, which led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>This G:C base pair is also the strongest determinant in phosphorylation of the MuSK NPXY site leading to recruitment of a phosphotyrosine-binding domain-containing protein (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>This G:C base pair is also the strongest determinant in phosphorylation of the MuSK NPXY site that leads to recruitment of a phosphotyrosine-binding domain-containing protein (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>This G:C base pair is also the strongest determinant in phosphorylation of the MuSK NPXY site which has led to recruitment of a phosphotyrosine-binding domain-containing protein (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>This G:C base pair is also the strongest determinant in phosphorylation of the MuSK NPXY site which leads to recruitment of a phosphotyrosine-binding domain-containing protein (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>This G:C base pair is also the strongest determinant in phosphorylation of the MuSK NPXY site which led to recruitment of a phosphotyrosine-binding domain-containing protein (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>This G:C base pair is also the strongest determinant in phosphorylation of the MuSK NPXY site, which led to recruitment of a phosphotyrosine-binding domain-containing protein (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>This can lead to a substantial diversity of nebulin and nebulette isoforms (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>This can lead to a substantial diversity of nebulin and nebulette isoforms, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>This can lead to synergistic activation of the ANF and other MEF2 target promoters (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>This can lead to synergistic activation of the ANF and other MEF2 target promoters, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>This can lead to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>This can lead us to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>This can lead us to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>This has led to a substantial diversity of nebulin and nebulette isoforms (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>This has led to a substantial diversity of nebulin and nebulette isoforms, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>This has led to synergistic activation of the ANF and other MEF2 target promoters (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>This has led to synergistic activation of the ANF and other MEF2 target promoters, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>This has led to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>This has led us to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>This has led us to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>This is able to lead to a substantial diversity of nebulin and nebulette isoforms (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>This is able to lead to synergistic activation of the ANF and other MEF2 target promoters (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>This is leading to a substantial diversity of nebulin and nebulette isoforms, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>This is leading to synergistic activation of the ANF and other MEF2 target promoters, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>This is leading to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>This lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>This lead to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>This leads to a substantial diversity of nebulin and nebulette isoforms (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>This leads to a substantial diversity of nebulin and nebulette isoforms, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>This leads to synergistic activation of the ANF and other MEF2 target promoters (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>This leads to synergistic activation of the ANF and other MEF2 target promoters, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>This leads to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>This leads us to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>This leads us to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>This led to a substantial diversity of nebulin and nebulette isoforms (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>This led to a substantial diversity of nebulin and nebulette isoforms, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>This led to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>This led to synergistic activation of the ANF and other MEF2 target promoters (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>This led to synergistic activation of the ANF and other MEF2 target promoters, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>This led to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>This led us to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>This led us to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>This may lead to a substantial diversity of nebulin and nebulette isoforms (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>This may lead to synergistic activation of the ANF and other MEF2 target promoters (Figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>This may lead to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>This that leads to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>This was caused by 7 missense mutations, 2 mutations leading to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>This was caused by 7 missense mutations, 2 mutations that leads to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>This was caused by 7 missense mutations, 2 mutations that led to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>This was caused by 7 missense mutations, 2 mutations which can lead to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>This was caused by 7 missense mutations, 2 mutations which has led to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>This was caused by 7 missense mutations, 2 mutations, which leads to frameshift.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>This was caused by Closer examination of the putative signal transduction pathway modulating htrA transcription leading to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>This was caused by Closer examination of the putative signal transduction pathway modulating htrA transcription that leads to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>This was caused by Closer examination of the putative signal transduction pathway modulating htrA transcription that led to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>This was caused by Closer examination of the putative signal transduction pathway modulating htrA transcription which can lead to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>This was caused by Closer examination of the putative signal transduction pathway modulating htrA transcription which has led to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>This was caused by Closer examination of the putative signal transduction pathway modulating htrA transcription, which leads to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>This was caused by Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leading to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>This was caused by Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D that leads to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>This was caused by Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D that led to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>This was caused by Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D which can lead to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>This was caused by Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D which has led to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>This was caused by Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D, which leads to a synergistic 40-to 50-fold activation of the ANF promoter.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>This was caused by Crl stimulates the activity of sigma (S) leading to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>This was caused by Crl stimulates the activity of sigma (S) that leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>This was caused by Crl stimulates the activity of sigma (S) that led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>This was caused by Crl stimulates the activity of sigma (S) which can lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>This was caused by Crl stimulates the activity of sigma (S) which has led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>This was caused by Crl stimulates the activity of sigma (S), which leads to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>This was caused by DNA (nCaRE)-ref1 interaction leading to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>This was caused by DNA (nCaRE)-ref1 interaction that leads to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>This was caused by DNA (nCaRE)-ref1 interaction that led to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>This was caused by DNA (nCaRE)-ref1 interaction which can lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>This was caused by DNA (nCaRE)-ref1 interaction which has led to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>This was caused by DNA (nCaRE)-ref1 interaction, which leads to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>This was caused by Genetic deficiency of GM2 activator leading to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>This was caused by Genetic deficiency of GM2 activator that leads to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>This was caused by Genetic deficiency of GM2 activator that led to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>This was caused by Genetic deficiency of GM2 activator which can lead to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>This was caused by Genetic deficiency of GM2 activator which has led to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>This was caused by Genetic deficiency of GM2 activator, which leads to a neurological disorder.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>This was caused by This leading to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>This was caused by This leading to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>This was caused by This that leads to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>This was caused by This that leads to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>This was caused by This that led to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>This was caused by This that led to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>This was caused by This which can lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>This was caused by This which can lead to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>This was caused by This which has led to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>This was caused by This which has led to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>This was caused by This, which leads to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>This was caused by This, which leads to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>This was caused by Transduction of the marA region from a Mar strain leading to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>This was caused by Transduction of the marA region from a Mar strain that leads to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>This was caused by Transduction of the marA region from a Mar strain that led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>This was caused by Transduction of the marA region from a Mar strain which can lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>This was caused by Transduction of the marA region from a Mar strain which has led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>This was caused by Transduction of the marA region from a Mar strain, which leads to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>This was caused by phosphorylation of the MuSK NPXY site leading to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>This was caused by phosphorylation of the MuSK NPXY site that leads to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>This was caused by phosphorylation of the MuSK NPXY site that led to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>This was caused by phosphorylation of the MuSK NPXY site which can lead to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>This was caused by phosphorylation of the MuSK NPXY site which has led to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>This was caused by phosphorylation of the MuSK NPXY site, which leads to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>This was caused by the sequence selection experiment leading to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>This was caused by the sequence selection experiment that leads to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>This was caused by the sequence selection experiment that led to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>This was caused by the sequence selection experiment which can lead to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>This was caused by the sequence selection experiment which has led to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>This was caused by the sequence selection experiment, which leads to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>This will lead us to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>This will lead us to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>This, but not a wild-type strain, led to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>This, but not a wild-type strain, led to synergistic activation of the ANF and other MEF2 target promoters.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>This, in turn, has led to a substantial diversity of nebulin and nebulette isoforms independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>This, in turn, is able to lead to a substantial diversity of nebulin and nebulette isoforms independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>This, in turn, is leading to a substantial diversity of nebulin and nebulette isoforms independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>This, in turn, leads to a substantial diversity of nebulin and nebulette isoforms independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>This, in turn, led to a substantial diversity of nebulin and nebulette isoforms independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>This, in turn, will lead to a substantial diversity of nebulin and nebulette isoforms independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>Transduction of the marA region from a Mar strain can lead to loss of OmpF (Figure 3A).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>Transduction of the marA region from a Mar strain can lead to loss of OmpF, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>Transduction of the marA region from a Mar strain can lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>Transduction of the marA region from a Mar strain can lead us to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>Transduction of the marA region from a Mar strain has led to loss of OmpF (Figure 3A).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>Transduction of the marA region from a Mar strain has led to loss of OmpF, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>Transduction of the marA region from a Mar strain has led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>Transduction of the marA region from a Mar strain has led us to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>Transduction of the marA region from a Mar strain is able to lead to loss of OmpF (Figure 3A).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>Transduction of the marA region from a Mar strain is leading to loss of OmpF, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>Transduction of the marA region from a Mar strain is leading to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>Transduction of the marA region from a Mar strain lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>Transduction of the marA region from a Mar strain leads to loss of OmpF (Figure 3A).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>Transduction of the marA region from a Mar strain leads to loss of OmpF, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>Transduction of the marA region from a Mar strain leads to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>Transduction of the marA region from a Mar strain leads us to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>Transduction of the marA region from a Mar strain led to loss of OmpF (Figure 3A).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>Transduction of the marA region from a Mar strain led to loss of OmpF, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>Transduction of the marA region from a Mar strain led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>Transduction of the marA region from a Mar strain led us to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>Transduction of the marA region from a Mar strain may lead to loss of OmpF (Figure 3A).</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>Transduction of the marA region from a Mar strain may lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>Transduction of the marA region from a Mar strain that leads to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>Transduction of the marA region from a Mar strain will lead us to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>Transduction of the marA region from a Mar strain, in turn, has led to loss of OmpF independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>Transduction of the marA region from a Mar strain, in turn, is able to lead to loss of OmpF independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>Transduction of the marA region from a Mar strain, in turn, is leading to loss of OmpF independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>Transduction of the marA region from a Mar strain, in turn, leads to loss of OmpF independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>Transduction of the marA region from a Mar strain, in turn, led to loss of OmpF independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>Transduction of the marA region from a Mar strain, in turn, will lead to loss of OmpF independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>a neurological disorder is led to by Genetic deficiency of GM2 activator.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>a neurological disorder was led to by Genetic deficiency of GM2 activator.</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>a point mutation (GTC----ATC) at codon 383 can lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Figure 3A).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>a point mutation (GTC----ATC) at codon 383 can lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>a point mutation (GTC----ATC) at codon 383 can lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>a point mutation (GTC----ATC) at codon 383 can lead us to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>a point mutation (GTC----ATC) at codon 383 has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Figure 3A).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>a point mutation (GTC----ATC) at codon 383 has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>a point mutation (GTC----ATC) at codon 383 has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>a point mutation (GTC----ATC) at codon 383 has led us to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>a point mutation (GTC----ATC) at codon 383 is able to lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Figure 3A).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>a point mutation (GTC----ATC) at codon 383 is leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>a point mutation (GTC----ATC) at codon 383 is leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>a point mutation (GTC----ATC) at codon 383 lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>a point mutation (GTC----ATC) at codon 383 leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Figure 3A).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>a point mutation (GTC----ATC) at codon 383 leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>a point mutation (GTC----ATC) at codon 383 leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>a point mutation (GTC----ATC) at codon 383 leads us to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>a point mutation (GTC----ATC) at codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Figure 3A).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>a point mutation (GTC----ATC) at codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>a point mutation (GTC----ATC) at codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>a point mutation (GTC----ATC) at codon 383 led us to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>a point mutation (GTC----ATC) at codon 383 may lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Figure 3A).</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>a point mutation (GTC----ATC) at codon 383 may lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>a point mutation (GTC----ATC) at codon 383 that leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>a point mutation (GTC----ATC) at codon 383 will lead us to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>a point mutation (GTC----ATC) at codon 383, but not a wild-type strain, led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>a point mutation (GTC----ATC) at codon 383, in turn, has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>a point mutation (GTC----ATC) at codon 383, in turn, is able to lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>a point mutation (GTC----ATC) at codon 383, in turn, is leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>a point mutation (GTC----ATC) at codon 383, in turn, leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>a point mutation (GTC----ATC) at codon 383, in turn, led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>a point mutation (GTC----ATC) at codon 383, in turn, will lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>a substantial diversity of nebulin and nebulette isoforms is led to by This.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>a substantial diversity of nebulin and nebulette isoforms was led to by This.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>a synergistic 40-to 50-fold activation of the ANF promoter is led to by Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>a synergistic 40-to 50-fold activation of the ANF promoter was led to by Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D.</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>frameshift is led to by 7 missense mutations, 2 mutations.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>frameshift was led to by 7 missense mutations, 2 mutations.</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>loss of OmpF is led to by Transduction of the marA region from a Mar strain.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>loss of OmpF was led to by Transduction of the marA region from a Mar strain.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="1">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>phosphorylation of the MuSK NPXY site can lead to recruitment of a phosphotyrosine-binding domain-containing protein (Figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>phosphorylation of the MuSK NPXY site can lead to recruitment of a phosphotyrosine-binding domain-containing protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>phosphorylation of the MuSK NPXY site can lead to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>phosphorylation of the MuSK NPXY site can lead us to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>phosphorylation of the MuSK NPXY site has led to recruitment of a phosphotyrosine-binding domain-containing protein (Figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>phosphorylation of the MuSK NPXY site has led to recruitment of a phosphotyrosine-binding domain-containing protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>phosphorylation of the MuSK NPXY site has led to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>phosphorylation of the MuSK NPXY site has led us to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>phosphorylation of the MuSK NPXY site is able to lead to recruitment of a phosphotyrosine-binding domain-containing protein (Figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>phosphorylation of the MuSK NPXY site is leading to recruitment of a phosphotyrosine-binding domain-containing protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>phosphorylation of the MuSK NPXY site is leading to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>phosphorylation of the MuSK NPXY site lead to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>phosphorylation of the MuSK NPXY site leads to recruitment of a phosphotyrosine-binding domain-containing protein (Figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>phosphorylation of the MuSK NPXY site leads to recruitment of a phosphotyrosine-binding domain-containing protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>phosphorylation of the MuSK NPXY site leads to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>phosphorylation of the MuSK NPXY site leads us to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>phosphorylation of the MuSK NPXY site led to recruitment of a phosphotyrosine-binding domain-containing protein (Figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>phosphorylation of the MuSK NPXY site led to recruitment of a phosphotyrosine-binding domain-containing protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>phosphorylation of the MuSK NPXY site led to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>phosphorylation of the MuSK NPXY site led us to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>phosphorylation of the MuSK NPXY site may lead to recruitment of a phosphotyrosine-binding domain-containing protein (Figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>phosphorylation of the MuSK NPXY site may lead to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>phosphorylation of the MuSK NPXY site that leads to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>phosphorylation of the MuSK NPXY site will lead us to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>phosphorylation of the MuSK NPXY site, but not a wild-type strain, led to recruitment of a phosphotyrosine-binding domain-containing protein.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>phosphorylation of the MuSK NPXY site, in turn, has led to recruitment of a phosphotyrosine-binding domain-containing protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>phosphorylation of the MuSK NPXY site, in turn, is able to lead to recruitment of a phosphotyrosine-binding domain-containing protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>phosphorylation of the MuSK NPXY site, in turn, is leading to recruitment of a phosphotyrosine-binding domain-containing protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>phosphorylation of the MuSK NPXY site, in turn, leads to recruitment of a phosphotyrosine-binding domain-containing protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>phosphorylation of the MuSK NPXY site, in turn, led to recruitment of a phosphotyrosine-binding domain-containing protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>phosphorylation of the MuSK NPXY site, in turn, will lead to recruitment of a phosphotyrosine-binding domain-containing protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>recruitment of a phosphotyrosine-binding domain-containing protein is led to by phosphorylation of the MuSK NPXY site.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>recruitment of a phosphotyrosine-binding domain-containing protein was led to by phosphorylation of the MuSK NPXY site.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>synergistic activation of the ANF and other MEF2 target promoters is led to by This.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>synergistic activation of the ANF and other MEF2 target promoters was led to by This.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter is led to by a point mutation (GTC----ATC) at codon 383.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter was led to by a point mutation (GTC----ATC) at codon 383.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>the identification of the BRE is led to by the sequence selection experiment.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>the identification of the BRE was led to by the sequence selection experiment.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>the identification of two new genes is led to by Closer examination of the putative signal transduction pathway modulating htrA transcription.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>the identification of two new genes was led to by Closer examination of the putative signal transduction pathway modulating htrA transcription.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>the sequence selection experiment can lead to the identification of the BRE (Figure 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>the sequence selection experiment can lead to the identification of the BRE, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>the sequence selection experiment can lead to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>the sequence selection experiment can lead us to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>the sequence selection experiment has led to the identification of the BRE (Figure 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>the sequence selection experiment has led to the identification of the BRE, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>the sequence selection experiment has led to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>the sequence selection experiment has led us to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>the sequence selection experiment is able to lead to the identification of the BRE (Figure 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>the sequence selection experiment is leading to the identification of the BRE, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>the sequence selection experiment is leading to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>the sequence selection experiment lead to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>the sequence selection experiment leads to the identification of the BRE (Figure 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>the sequence selection experiment leads to the identification of the BRE, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>the sequence selection experiment leads to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>the sequence selection experiment leads us to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>the sequence selection experiment led to the identification of the BRE (Figure 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>the sequence selection experiment led to the identification of the BRE, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>the sequence selection experiment led to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>the sequence selection experiment led us to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>the sequence selection experiment may lead to the identification of the BRE (Figure 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>the sequence selection experiment may lead to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>the sequence selection experiment that leads to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>the sequence selection experiment will lead us to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>the sequence selection experiment, but not a wild-type strain, led to the identification of the BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>the sequence selection experiment, in turn, has led to the identification of the BRE independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>the sequence selection experiment, in turn, is able to lead to the identification of the BRE independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>the sequence selection experiment, in turn, is leading to the identification of the BRE independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>the sequence selection experiment, in turn, leads to the identification of the BRE independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>the sequence selection experiment, in turn, led to the identification of the BRE independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>the sequence selection experiment, in turn, will lead to the identification of the BRE independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Disruption of the SNU246 gene in yeast leading to a splicing defect in vivo, indicating that the protein is essential for splicing, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Disruption of the SNU246 gene in yeast that lead to a splicing defect in vivo, indicating that the protein is essential for splicing, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Disruption of the SNU246 gene in yeast that led to a splicing defect in vivo, indicating that the protein is essential for splicing, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Disruption of the SNU246 gene in yeast which lead to a splicing defect in vivo, indicating that the protein is essential for splicing, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Disruption of the SNU246 gene in yeast which led to a splicing defect in vivo, indicating that the protein is essential for splicing, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 that lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 which lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 that lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 which lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Growth of Escherichia coli in the presence of nitrate or nitrite leading to a 45% decrease in expression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Growth of Escherichia coli in the presence of nitrate or nitrite that lead to a 45% decrease in expression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% decrease in expression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Growth of Escherichia coli in the presence of nitrate or nitrite which lead to a 45% decrease in expression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (Growth of Escherichia coli in the presence of nitrate or nitrite which led to a 45% decrease in expression, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The loss of TreR function leading to derepression of treB, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The loss of TreR function that lead to derepression of treB, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The loss of TreR function that led to derepression of treB, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The loss of TreR function which lead to derepression of treB, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The loss of TreR function which led to derepression of treB, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The splice mutation in 5 end of intron 5 that lead to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The splice mutation in 5 end of intron 5 that led to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The splice mutation in 5 end of intron 5 which lead to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (The splice mutation in 5 end of intron 5 which led to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This splice mutation in 5 end of intron 5 that lead to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This splice mutation in 5 end of intron 5 that led to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This splice mutation in 5 end of intron 5 which lead to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (This splice mutation in 5 end of intron 5 which led to abnormal splice in exon 5 and exon 6, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a complex splice site mutation leading to an abnormal JAG1 mRNA, resulting in a premature stop codon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a complex splice site mutation that lead to an abnormal JAG1 mRNA, resulting in a premature stop codon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a complex splice site mutation that led to an abnormal JAG1 mRNA, resulting in a premature stop codon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a complex splice site mutation which lead to an abnormal JAG1 mRNA, resulting in a premature stop codon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a complex splice site mutation which led to an abnormal JAG1 mRNA, resulting in a premature stop codon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation at the 5 splicing site of the third intron leading to ligation of the second to the fourth exon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation at the 5 splicing site of the third intron that lead to ligation of the second to the fourth exon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation at the 5 splicing site of the third intron that led to ligation of the second to the fourth exon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation at the 5 splicing site of the third intron which lead to ligation of the second to the fourth exon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (a point mutation at the 5 splicing site of the third intron which led to ligation of the second to the fourth exon, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (inactivation of the MEF2C gene leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (inactivation of the MEF2C gene that lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (inactivation of the MEF2C gene that led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (inactivation of the MEF2C gene which lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (inactivation of the MEF2C gene which led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the distinct amino termini leading to the targeting of individual VDAC isoforms to different cellular compartments, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the distinct amino termini that lead to the targeting of individual VDAC isoforms to different cellular compartments, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the distinct amino termini that led to the targeting of individual VDAC isoforms to different cellular compartments, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the distinct amino termini which lead to the targeting of individual VDAC isoforms to different cellular compartments, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (the distinct amino termini which led to the targeting of individual VDAC isoforms to different cellular compartments, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (two frameshifts and a splice site mutation leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (two frameshifts and a splice site mutation that lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (two frameshifts and a splice site mutation that led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (two frameshifts and a splice site mutation which lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (two frameshifts and a splice site mutation which led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Disruption of the SNU246 gene in yeast G:C base pair is also the strongest determinant in This leading to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Disruption of the SNU246 gene in yeast G:C base pair is also the strongest determinant in This that leads to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Disruption of the SNU246 gene in yeast G:C base pair is also the strongest determinant in This which has led to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Disruption of the SNU246 gene in yeast G:C base pair is also the strongest determinant in This which leads to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>Disruption of the SNU246 gene in yeast G:C base pair is also the strongest determinant in This which led to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>Disruption of the SNU246 gene in yeast G:C base pair is also the strongest determinant in This, which led to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>Disruption of the SNU246 gene in yeast can lead to a splicing defect in vivo, indicating that the protein is essential for splicing (Figure 3A).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>Disruption of the SNU246 gene in yeast can lead to a splicing defect in vivo, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>Disruption of the SNU246 gene in yeast can lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>Disruption of the SNU246 gene in yeast can lead us to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>Disruption of the SNU246 gene in yeast has led to a splicing defect in vivo, indicating that the protein is essential for splicing (Figure 3A).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>Disruption of the SNU246 gene in yeast has led to a splicing defect in vivo, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>Disruption of the SNU246 gene in yeast has led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>Disruption of the SNU246 gene in yeast has led us to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>Disruption of the SNU246 gene in yeast is able to lead to a splicing defect in vivo, indicating that the protein is essential for splicing (Figure 3A).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>Disruption of the SNU246 gene in yeast is leading to a splicing defect in vivo, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>Disruption of the SNU246 gene in yeast is leading to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>Disruption of the SNU246 gene in yeast lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>Disruption of the SNU246 gene in yeast leads to a splicing defect in vivo, indicating that the protein is essential for splicing (Figure 3A).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>Disruption of the SNU246 gene in yeast leads to a splicing defect in vivo, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>Disruption of the SNU246 gene in yeast leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>Disruption of the SNU246 gene in yeast leads us to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>Disruption of the SNU246 gene in yeast led to a splicing defect in vivo, indicating that the protein is essential for splicing (Figure 3A).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>Disruption of the SNU246 gene in yeast led to a splicing defect in vivo, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>Disruption of the SNU246 gene in yeast led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>Disruption of the SNU246 gene in yeast led us to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>Disruption of the SNU246 gene in yeast may lead to a splicing defect in vivo, indicating that the protein is essential for splicing (Figure 3A).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>Disruption of the SNU246 gene in yeast may lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>Disruption of the SNU246 gene in yeast that leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>Disruption of the SNU246 gene in yeast was caused by This leading to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>Disruption of the SNU246 gene in yeast was caused by This that leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>Disruption of the SNU246 gene in yeast was caused by This that led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>Disruption of the SNU246 gene in yeast was caused by This which can lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>Disruption of the SNU246 gene in yeast was caused by This which has led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Disruption of the SNU246 gene in yeast was caused by This, which leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Disruption of the SNU246 gene in yeast will lead us to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Disruption of the SNU246 gene in yeast, but not a wild-type strain, led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Disruption of the SNU246 gene in yeast, in turn, has led to a splicing defect in vivo, indicating that the protein is essential for splicing independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Disruption of the SNU246 gene in yeast, in turn, is able to lead to a splicing defect in vivo, indicating that the protein is essential for splicing independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Disruption of the SNU246 gene in yeast, in turn, is leading to a splicing defect in vivo, indicating that the protein is essential for splicing independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Disruption of the SNU246 gene in yeast, in turn, leads to a splicing defect in vivo, indicating that the protein is essential for splicing independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>Disruption of the SNU246 gene in yeast, in turn, led to a splicing defect in vivo, indicating that the protein is essential for splicing independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>Disruption of the SNU246 gene in yeast, in turn, will lead to a splicing defect in vivo, indicating that the protein is essential for splicing independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Disruption of the SNU246 gene in yeast could lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Disruption of the SNU246 gene in yeast had led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Disruption of the SNU246 gene in yeast led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Disruption of the SNU246 gene in yeast was able to lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 could lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 had led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 could lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 had led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Growth of Escherichia coli in the presence of nitrate or nitrite could lead to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Growth of Escherichia coli in the presence of nitrate or nitrite had led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that Growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that The loss of TreR function could lead to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that The loss of TreR function had led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that The loss of TreR function led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that The loss of TreR function was able to lead to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that The splice mutation in 5 end of intron 5 could lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that The splice mutation in 5 end of intron 5 had led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that The splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that The splice mutation in 5 end of intron 5 was able to lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This splice mutation in 5 end of intron 5 could lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This splice mutation in 5 end of intron 5 had led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that This splice mutation in 5 end of intron 5 was able to lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele could lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele had led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele was able to lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a complex splice site mutation could lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a complex splice site mutation had led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a complex splice site mutation led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a complex splice site mutation was able to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a point mutation at the 5 splicing site of the third intron could lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a point mutation at the 5 splicing site of the third intron had led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a point mutation at the 5 splicing site of the third intron led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that a point mutation at the 5 splicing site of the third intron was able to lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that inactivation of the MEF2C gene could lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that inactivation of the MEF2C gene had led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that inactivation of the MEF2C gene led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that inactivation of the MEF2C gene was able to lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that the distinct amino termini could lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that the distinct amino termini had led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that the distinct amino termini led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that the distinct amino termini was able to lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that two frameshifts and a splice site mutation could lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that two frameshifts and a splice site mutation had led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that two frameshifts and a splice site mutation led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that two frameshifts and a splice site mutation was able to lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Disruption of the SNU246 gene in yeast is able to lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Disruption of the SNU246 gene in yeast leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Growth of Escherichia coli in the presence of nitrate or nitrite is able to lead to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that Growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that The loss of TreR function is able to lead to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that The loss of TreR function leads to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that The splice mutation in 5 end of intron 5 is able to lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that The splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that This splice mutation in 5 end of intron 5 is able to lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that This splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele is able to lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that a complex splice site mutation is able to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that a complex splice site mutation leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that a point mutation at the 5 splicing site of the third intron is able to lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that a point mutation at the 5 splicing site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that inactivation of the MEF2C gene is able to lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that inactivation of the MEF2C gene leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that the distinct amino termini is able to lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that the distinct amino termini leads to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that two frameshifts and a splice site mutation is able to lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that two frameshifts and a splice site mutation leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This, which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 has led us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leads us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 led us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This which can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This, which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 will lead us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, but not a wild-type strain, led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 G:C base pair is also the strongest determinant in This, which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 has led us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leads us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 led us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Figure 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This which can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 was caused by This, which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 will lead us to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, but not a wild-type strain, led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, in turn, will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite G:C base pair is also the strongest determinant in This leading to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite G:C base pair is also the strongest determinant in This that leads to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite G:C base pair is also the strongest determinant in This which has led to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite G:C base pair is also the strongest determinant in This which leads to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite G:C base pair is also the strongest determinant in This which led to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite G:C base pair is also the strongest determinant in This, which led to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% decrease in expression (Figure 3A).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% decrease in expression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite can lead us to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite has led to a 45% decrease in expression (Figure 3A).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite has led to a 45% decrease in expression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite has led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite has led us to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite is able to lead to a 45% decrease in expression (Figure 3A).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite is leading to a 45% decrease in expression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite is leading to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite lead to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression (Figure 3A).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite leads us to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression (Figure 3A).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite led us to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite may lead to a 45% decrease in expression (Figure 3A).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite may lead to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite that leads to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite was caused by This leading to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite was caused by This that leads to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite was caused by This that led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite was caused by This which can lead to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite was caused by This which has led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite was caused by This, which leads to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite will lead us to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite, but not a wild-type strain, led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite, in turn, has led to a 45% decrease in expression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite, in turn, is able to lead to a 45% decrease in expression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite, in turn, is leading to a 45% decrease in expression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite, in turn, leads to a 45% decrease in expression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite, in turn, led to a 45% decrease in expression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite, in turn, will lead to a 45% decrease in expression independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>It has been shown that Disruption of the SNU246 gene in yeast, leading to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>It has been shown that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>It has been shown that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>It has been shown that Growth of Escherichia coli in the presence of nitrate or nitrite, leading to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>It has been shown that The loss of TreR function, leading to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>It has been shown that The splice mutation in 5 end of intron 5, leading to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>It has been shown that This splice mutation in 5 end of intron 5, leading to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>It has been shown that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>It has been shown that a complex splice site mutation, leading to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>It has been shown that a point mutation at the 5 splicing site of the third intron, leading to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>It has been shown that inactivation of the MEF2C gene, leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>It has been shown that the distinct amino termini, leading to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>It has been shown that two frameshifts and a splice site mutation, leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>The loss of TreR function G:C base pair is also the strongest determinant in This leading to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>The loss of TreR function G:C base pair is also the strongest determinant in This that leads to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>The loss of TreR function G:C base pair is also the strongest determinant in This which has led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>The loss of TreR function G:C base pair is also the strongest determinant in This which leads to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>The loss of TreR function G:C base pair is also the strongest determinant in This which led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>The loss of TreR function G:C base pair is also the strongest determinant in This, which led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>The loss of TreR function can lead to derepression of treB (Figure 3A).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>The loss of TreR function can lead to derepression of treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>The loss of TreR function can lead to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>The loss of TreR function can lead us to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>The loss of TreR function has led to derepression of treB (Figure 3A).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>The loss of TreR function has led to derepression of treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>The loss of TreR function has led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>The loss of TreR function has led us to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>The loss of TreR function is able to lead to derepression of treB (Figure 3A).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>The loss of TreR function is leading to derepression of treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>The loss of TreR function is leading to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>The loss of TreR function lead to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>The loss of TreR function leads to derepression of treB (Figure 3A).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>The loss of TreR function leads to derepression of treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>The loss of TreR function leads to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>The loss of TreR function leads us to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>The loss of TreR function led to derepression of treB (Figure 3A).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>The loss of TreR function led to derepression of treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>The loss of TreR function led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>The loss of TreR function led us to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>The loss of TreR function may lead to derepression of treB (Figure 3A).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>The loss of TreR function may lead to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>The loss of TreR function that leads to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>The loss of TreR function was caused by This leading to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>The loss of TreR function was caused by This that leads to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>The loss of TreR function was caused by This that led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>The loss of TreR function was caused by This which can lead to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>The loss of TreR function was caused by This which has led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>The loss of TreR function was caused by This, which leads to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>The loss of TreR function will lead us to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>The loss of TreR function, but not a wild-type strain, led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>The loss of TreR function, in turn, has led to derepression of treB independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>The loss of TreR function, in turn, is able to lead to derepression of treB independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>The loss of TreR function, in turn, is leading to derepression of treB independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>The loss of TreR function, in turn, leads to derepression of treB independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>The loss of TreR function, in turn, led to derepression of treB independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>The loss of TreR function, in turn, will lead to derepression of treB independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>The splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This leading to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>The splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This that leads to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>The splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This which has led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>The splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This which leads to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>The splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This which led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>The splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This, which led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>The splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>The splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>The splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>The splice mutation in 5 end of intron 5 can lead us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>The splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>The splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>The splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>The splice mutation in 5 end of intron 5 has led us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>The splice mutation in 5 end of intron 5 is able to lead to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>The splice mutation in 5 end of intron 5 is leading to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>The splice mutation in 5 end of intron 5 is leading to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>The splice mutation in 5 end of intron 5 lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>The splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>The splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>The splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>The splice mutation in 5 end of intron 5 leads us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>The splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>The splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>The splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>The splice mutation in 5 end of intron 5 led us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>The splice mutation in 5 end of intron 5 may lead to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>The splice mutation in 5 end of intron 5 may lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>The splice mutation in 5 end of intron 5 that leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>The splice mutation in 5 end of intron 5 was caused by This leading to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>The splice mutation in 5 end of intron 5 was caused by This that leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>The splice mutation in 5 end of intron 5 was caused by This that led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>The splice mutation in 5 end of intron 5 was caused by This which can lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>The splice mutation in 5 end of intron 5 was caused by This which has led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>The splice mutation in 5 end of intron 5 was caused by This, which leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>The splice mutation in 5 end of intron 5 will lead us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>The splice mutation in 5 end of intron 5, but not a wild-type strain, led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>The splice mutation in 5 end of intron 5, in turn, has led to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>The splice mutation in 5 end of intron 5, in turn, is able to lead to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>The splice mutation in 5 end of intron 5, in turn, is leading to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>The splice mutation in 5 end of intron 5, in turn, leads to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>The splice mutation in 5 end of intron 5, in turn, led to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>The splice mutation in 5 end of intron 5, in turn, will lead to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>These data suggest that Disruption of the SNU246 gene in yeast can lead to a splicing defect in vivo, indicating that the protein is essential for splicing that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>These data suggest that Disruption of the SNU246 gene in yeast has led to a splicing defect in vivo, indicating that the protein is essential for splicing that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>These data suggest that Disruption of the SNU246 gene in yeast leads to a splicing defect in vivo, indicating that the protein is essential for splicing that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>These data suggest that Disruption of the SNU246 gene in yeast will lead to a splicing defect in vivo, indicating that the protein is essential for splicing that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>These data suggest that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>These data suggest that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>These data suggest that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>These data suggest that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>These data suggest that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>These data suggest that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>These data suggest that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>These data suggest that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>These data suggest that Growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% decrease in expression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>These data suggest that Growth of Escherichia coli in the presence of nitrate or nitrite has led to a 45% decrease in expression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>These data suggest that Growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>These data suggest that Growth of Escherichia coli in the presence of nitrate or nitrite will lead to a 45% decrease in expression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>These data suggest that The loss of TreR function can lead to derepression of treB that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>These data suggest that The loss of TreR function has led to derepression of treB that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>These data suggest that The loss of TreR function leads to derepression of treB that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>These data suggest that The loss of TreR function will lead to derepression of treB that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>These data suggest that The splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>These data suggest that The splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>These data suggest that The splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>These data suggest that The splice mutation in 5 end of intron 5 will lead to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>These data suggest that This splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>These data suggest that This splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>These data suggest that This splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>These data suggest that This splice mutation in 5 end of intron 5 will lead to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>These data suggest that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele can lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>These data suggest that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>These data suggest that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>These data suggest that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele will lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>These data suggest that a complex splice site mutation can lead to an abnormal JAG1 mRNA, resulting in a premature stop codon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>These data suggest that a complex splice site mutation has led to an abnormal JAG1 mRNA, resulting in a premature stop codon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>These data suggest that a complex splice site mutation leads to an abnormal JAG1 mRNA, resulting in a premature stop codon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>These data suggest that a complex splice site mutation will lead to an abnormal JAG1 mRNA, resulting in a premature stop codon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>These data suggest that a point mutation at the 5 splicing site of the third intron can lead to ligation of the second to the fourth exon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>These data suggest that a point mutation at the 5 splicing site of the third intron has led to ligation of the second to the fourth exon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>These data suggest that a point mutation at the 5 splicing site of the third intron leads to ligation of the second to the fourth exon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>These data suggest that a point mutation at the 5 splicing site of the third intron will lead to ligation of the second to the fourth exon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>These data suggest that inactivation of the MEF2C gene can lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>These data suggest that inactivation of the MEF2C gene has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>These data suggest that inactivation of the MEF2C gene leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>These data suggest that inactivation of the MEF2C gene will lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>These data suggest that the distinct amino termini can lead to the targeting of individual VDAC isoforms to different cellular compartments that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>These data suggest that the distinct amino termini has led to the targeting of individual VDAC isoforms to different cellular compartments that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>These data suggest that the distinct amino termini leads to the targeting of individual VDAC isoforms to different cellular compartments that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>These data suggest that the distinct amino termini will lead to the targeting of individual VDAC isoforms to different cellular compartments that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>These data suggest that two frameshifts and a splice site mutation can lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>These data suggest that two frameshifts and a splice site mutation has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>These data suggest that two frameshifts and a splice site mutation leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>These data suggest that two frameshifts and a splice site mutation will lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>These data suggested that Disruption of the SNU246 gene in yeast led to a splicing defect in vivo, indicating that the protein is essential for splicing that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>These data suggested that Disruption of the SNU246 gene in yeast was able to lead to a splicing defect in vivo, indicating that the protein is essential for splicing that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>These data suggested that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>These data suggested that G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>These data suggested that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>These data suggested that G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>These data suggested that Growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>These data suggested that Growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% decrease in expression that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>These data suggested that The loss of TreR function led to derepression of treB that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>These data suggested that The loss of TreR function was able to lead to derepression of treB that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>These data suggested that The splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>These data suggested that The splice mutation in 5 end of intron 5 was able to lead to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>These data suggested that This splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>These data suggested that This splice mutation in 5 end of intron 5 was able to lead to abnormal splice in exon 5 and exon 6 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>These data suggested that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>These data suggested that a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele was able to lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>These data suggested that a complex splice site mutation led to an abnormal JAG1 mRNA, resulting in a premature stop codon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>These data suggested that a complex splice site mutation was able to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>These data suggested that a point mutation at the 5 splicing site of the third intron led to ligation of the second to the fourth exon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>These data suggested that a point mutation at the 5 splicing site of the third intron was able to lead to ligation of the second to the fourth exon that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>These data suggested that inactivation of the MEF2C gene led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>These data suggested that inactivation of the MEF2C gene was able to lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>These data suggested that the distinct amino termini led to the targeting of individual VDAC isoforms to different cellular compartments that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>These data suggested that the distinct amino termini was able to lead to the targeting of individual VDAC isoforms to different cellular compartments that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>These data suggested that two frameshifts and a splice site mutation led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>These data suggested that two frameshifts and a splice site mutation was able to lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>This G:C base pair is also the strongest determinant in Disruption of the SNU246 gene in yeast leading to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>This G:C base pair is also the strongest determinant in Disruption of the SNU246 gene in yeast that leads to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>This G:C base pair is also the strongest determinant in Disruption of the SNU246 gene in yeast which has led to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>This G:C base pair is also the strongest determinant in Disruption of the SNU246 gene in yeast which leads to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>This G:C base pair is also the strongest determinant in Disruption of the SNU246 gene in yeast which led to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>This G:C base pair is also the strongest determinant in Disruption of the SNU246 gene in yeast, which led to a splicing defect in vivo, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>This G:C base pair is also the strongest determinant in G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>This G:C base pair is also the strongest determinant in G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>This G:C base pair is also the strongest determinant in G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>This G:C base pair is also the strongest determinant in G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>This G:C base pair is also the strongest determinant in G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>This G:C base pair is also the strongest determinant in G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>This G:C base pair is also the strongest determinant in G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>This G:C base pair is also the strongest determinant in G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>This G:C base pair is also the strongest determinant in G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>This G:C base pair is also the strongest determinant in G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>This G:C base pair is also the strongest determinant in G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>This G:C base pair is also the strongest determinant in G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>This G:C base pair is also the strongest determinant in Growth of Escherichia coli in the presence of nitrate or nitrite leading to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>This G:C base pair is also the strongest determinant in Growth of Escherichia coli in the presence of nitrate or nitrite that leads to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>This G:C base pair is also the strongest determinant in Growth of Escherichia coli in the presence of nitrate or nitrite which has led to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>This G:C base pair is also the strongest determinant in Growth of Escherichia coli in the presence of nitrate or nitrite which leads to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>This G:C base pair is also the strongest determinant in Growth of Escherichia coli in the presence of nitrate or nitrite which led to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>This G:C base pair is also the strongest determinant in Growth of Escherichia coli in the presence of nitrate or nitrite, which led to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>This G:C base pair is also the strongest determinant in The loss of TreR function leading to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>This G:C base pair is also the strongest determinant in The loss of TreR function that leads to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>This G:C base pair is also the strongest determinant in The loss of TreR function which has led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>This G:C base pair is also the strongest determinant in The loss of TreR function which leads to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>This G:C base pair is also the strongest determinant in The loss of TreR function which led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>This G:C base pair is also the strongest determinant in The loss of TreR function, which led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>This G:C base pair is also the strongest determinant in The splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>This G:C base pair is also the strongest determinant in The splice mutation in 5 end of intron 5 that leads to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>This G:C base pair is also the strongest determinant in The splice mutation in 5 end of intron 5 which has led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>This G:C base pair is also the strongest determinant in The splice mutation in 5 end of intron 5 which leads to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>This G:C base pair is also the strongest determinant in The splice mutation in 5 end of intron 5 which led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>This G:C base pair is also the strongest determinant in The splice mutation in 5 end of intron 5, which led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>This G:C base pair is also the strongest determinant in This splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>This G:C base pair is also the strongest determinant in This splice mutation in 5 end of intron 5 that leads to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>This G:C base pair is also the strongest determinant in This splice mutation in 5 end of intron 5 which has led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>This G:C base pair is also the strongest determinant in This splice mutation in 5 end of intron 5 which leads to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>This G:C base pair is also the strongest determinant in This splice mutation in 5 end of intron 5 which led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>This G:C base pair is also the strongest determinant in This splice mutation in 5 end of intron 5, which led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>This G:C base pair is also the strongest determinant in a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>This G:C base pair is also the strongest determinant in a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>This G:C base pair is also the strongest determinant in a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>This G:C base pair is also the strongest determinant in a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>This G:C base pair is also the strongest determinant in a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>This G:C base pair is also the strongest determinant in a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, which led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>This G:C base pair is also the strongest determinant in a complex splice site mutation leading to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>This G:C base pair is also the strongest determinant in a complex splice site mutation that leads to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>This G:C base pair is also the strongest determinant in a complex splice site mutation which has led to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>This G:C base pair is also the strongest determinant in a complex splice site mutation which leads to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>This G:C base pair is also the strongest determinant in a complex splice site mutation which led to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>This G:C base pair is also the strongest determinant in a complex splice site mutation, which led to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>This G:C base pair is also the strongest determinant in a point mutation at the 5 splicing site of the third intron leading to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>This G:C base pair is also the strongest determinant in a point mutation at the 5 splicing site of the third intron that leads to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>This G:C base pair is also the strongest determinant in a point mutation at the 5 splicing site of the third intron which has led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>This G:C base pair is also the strongest determinant in a point mutation at the 5 splicing site of the third intron which leads to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>This G:C base pair is also the strongest determinant in a point mutation at the 5 splicing site of the third intron which led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>This G:C base pair is also the strongest determinant in a point mutation at the 5 splicing site of the third intron, which led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>This G:C base pair is also the strongest determinant in inactivation of the MEF2C gene leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>This G:C base pair is also the strongest determinant in inactivation of the MEF2C gene that leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>This G:C base pair is also the strongest determinant in inactivation of the MEF2C gene which has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>This G:C base pair is also the strongest determinant in inactivation of the MEF2C gene which leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>This G:C base pair is also the strongest determinant in inactivation of the MEF2C gene which led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>This G:C base pair is also the strongest determinant in inactivation of the MEF2C gene, which led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>This G:C base pair is also the strongest determinant in the distinct amino termini leading to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>This G:C base pair is also the strongest determinant in the distinct amino termini that leads to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>This G:C base pair is also the strongest determinant in the distinct amino termini which has led to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>This G:C base pair is also the strongest determinant in the distinct amino termini which leads to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>This G:C base pair is also the strongest determinant in the distinct amino termini which led to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>This G:C base pair is also the strongest determinant in the distinct amino termini, which led to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>This G:C base pair is also the strongest determinant in two frameshifts and a splice site mutation leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>This G:C base pair is also the strongest determinant in two frameshifts and a splice site mutation that leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>This G:C base pair is also the strongest determinant in two frameshifts and a splice site mutation which has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>This G:C base pair is also the strongest determinant in two frameshifts and a splice site mutation which leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>This G:C base pair is also the strongest determinant in two frameshifts and a splice site mutation which led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>This G:C base pair is also the strongest determinant in two frameshifts and a splice site mutation, which led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>This splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This leading to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>This splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This that leads to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>This splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This which has led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>This splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This which leads to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>This splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This which led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>This splice mutation in 5 end of intron 5 G:C base pair is also the strongest determinant in This, which led to abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>This splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>This splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>This splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>This splice mutation in 5 end of intron 5 can lead us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>This splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>This splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>This splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>This splice mutation in 5 end of intron 5 has led us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>This splice mutation in 5 end of intron 5 is able to lead to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>This splice mutation in 5 end of intron 5 is leading to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>This splice mutation in 5 end of intron 5 is leading to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>This splice mutation in 5 end of intron 5 lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>This splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>This splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>This splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>This splice mutation in 5 end of intron 5 leads us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>This splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>This splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>This splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>This splice mutation in 5 end of intron 5 led us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>This splice mutation in 5 end of intron 5 may lead to abnormal splice in exon 5 and exon 6 (Figure 3A).</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>This splice mutation in 5 end of intron 5 may lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>This splice mutation in 5 end of intron 5 that leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>This splice mutation in 5 end of intron 5 was caused by This leading to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>This splice mutation in 5 end of intron 5 was caused by This that leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>This splice mutation in 5 end of intron 5 was caused by This that led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>This splice mutation in 5 end of intron 5 was caused by This which can lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>This splice mutation in 5 end of intron 5 was caused by This which has led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>This splice mutation in 5 end of intron 5 was caused by This, which leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>This splice mutation in 5 end of intron 5 will lead us to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>This splice mutation in 5 end of intron 5, but not a wild-type strain, led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>This splice mutation in 5 end of intron 5, in turn, has led to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>This splice mutation in 5 end of intron 5, in turn, is able to lead to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>This splice mutation in 5 end of intron 5, in turn, is leading to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>This splice mutation in 5 end of intron 5, in turn, leads to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>This splice mutation in 5 end of intron 5, in turn, led to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>This splice mutation in 5 end of intron 5, in turn, will lead to abnormal splice in exon 5 and exon 6 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>This was caused by Disruption of the SNU246 gene in yeast leading to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>This was caused by Disruption of the SNU246 gene in yeast that leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>This was caused by Disruption of the SNU246 gene in yeast that led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>This was caused by Disruption of the SNU246 gene in yeast which can lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>This was caused by Disruption of the SNU246 gene in yeast which has led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>This was caused by Disruption of the SNU246 gene in yeast, which leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>This was caused by G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>This was caused by G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>This was caused by G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>This was caused by G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 which can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>This was caused by G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>This was caused by G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14, which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>This was caused by G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>This was caused by G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>This was caused by G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>This was caused by G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 which can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>This was caused by G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>This was caused by G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14, which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>This was caused by Growth of Escherichia coli in the presence of nitrate or nitrite leading to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>This was caused by Growth of Escherichia coli in the presence of nitrate or nitrite that leads to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>This was caused by Growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>This was caused by Growth of Escherichia coli in the presence of nitrate or nitrite which can lead to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>This was caused by Growth of Escherichia coli in the presence of nitrate or nitrite which has led to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>This was caused by Growth of Escherichia coli in the presence of nitrate or nitrite, which leads to a 45% decrease in expression.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>This was caused by The loss of TreR function leading to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>This was caused by The loss of TreR function that leads to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>This was caused by The loss of TreR function that led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>This was caused by The loss of TreR function which can lead to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>This was caused by The loss of TreR function which has led to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>This was caused by The loss of TreR function, which leads to derepression of treB.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>This was caused by The splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>This was caused by The splice mutation in 5 end of intron 5 that leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>This was caused by The splice mutation in 5 end of intron 5 that led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>This was caused by The splice mutation in 5 end of intron 5 which can lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>This was caused by The splice mutation in 5 end of intron 5 which has led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>This was caused by The splice mutation in 5 end of intron 5, which leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>This was caused by This splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>This was caused by This splice mutation in 5 end of intron 5 that leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>This was caused by This splice mutation in 5 end of intron 5 that led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>This was caused by This splice mutation in 5 end of intron 5 which can lead to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>This was caused by This splice mutation in 5 end of intron 5 which has led to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>This was caused by This splice mutation in 5 end of intron 5, which leads to abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>This was caused by a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>This was caused by a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>This was caused by a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>This was caused by a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which can lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>This was caused by a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>This was caused by a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, which leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>This was caused by a complex splice site mutation leading to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>This was caused by a complex splice site mutation that leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>This was caused by a complex splice site mutation that led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>This was caused by a complex splice site mutation which can lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>This was caused by a complex splice site mutation which has led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>This was caused by a complex splice site mutation, which leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>This was caused by a point mutation at the 5 splicing site of the third intron leading to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>This was caused by a point mutation at the 5 splicing site of the third intron that leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="666">
                    <text>This was caused by a point mutation at the 5 splicing site of the third intron that led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="667">
                    <text>This was caused by a point mutation at the 5 splicing site of the third intron which can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="668">
                    <text>This was caused by a point mutation at the 5 splicing site of the third intron which has led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="669">
                    <text>This was caused by a point mutation at the 5 splicing site of the third intron, which leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="670">
                    <text>This was caused by inactivation of the MEF2C gene leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="671">
                    <text>This was caused by inactivation of the MEF2C gene that leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="672">
                    <text>This was caused by inactivation of the MEF2C gene that led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="673">
                    <text>This was caused by inactivation of the MEF2C gene which can lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="674">
                    <text>This was caused by inactivation of the MEF2C gene which has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="675">
                    <text>This was caused by inactivation of the MEF2C gene, which leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="676">
                    <text>This was caused by the distinct amino termini leading to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="677">
                    <text>This was caused by the distinct amino termini that leads to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="678">
                    <text>This was caused by the distinct amino termini that led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="679">
                    <text>This was caused by the distinct amino termini which can lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="680">
                    <text>This was caused by the distinct amino termini which has led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="681">
                    <text>This was caused by the distinct amino termini, which leads to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="682">
                    <text>This was caused by two frameshifts and a splice site mutation leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="683">
                    <text>This was caused by two frameshifts and a splice site mutation that leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="684">
                    <text>This was caused by two frameshifts and a splice site mutation that led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="685">
                    <text>This was caused by two frameshifts and a splice site mutation which can lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="686">
                    <text>This was caused by two frameshifts and a splice site mutation which has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="687">
                    <text>This was caused by two frameshifts and a splice site mutation, which leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="688">
                    <text>a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein is led to by a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="689">
                    <text>a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein was led to by a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="690">
                    <text>a 45% decrease in expression is led to by Growth of Escherichia coli in the presence of nitrate or nitrite.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="691">
                    <text>a 45% decrease in expression was led to by Growth of Escherichia coli in the presence of nitrate or nitrite.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="692">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele G:C base pair is also the strongest determinant in This leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="693">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele G:C base pair is also the strongest determinant in This that leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="694">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele G:C base pair is also the strongest determinant in This which has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="695">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele G:C base pair is also the strongest determinant in This which leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="696">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele G:C base pair is also the strongest determinant in This which led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="697">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele G:C base pair is also the strongest determinant in This, which led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="698">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele can lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Figure 3A).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="699">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele can lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="700">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele can lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="701">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele can lead us to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="702">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Figure 3A).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="703">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="704">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="705">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele has led us to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="706">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele is able to lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Figure 3A).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="707">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele is leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="708">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele is leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="709">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="710">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Figure 3A).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="711">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="712">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="713">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele leads us to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="714">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Figure 3A).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="715">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="716">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="717">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele led us to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="718">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele may lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein (Figure 3A).</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="719">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele may lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="720">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="721">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele was caused by This leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="722">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele was caused by This that leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="723">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele was caused by This that led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="724">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele was caused by This which can lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="725">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele was caused by This which has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="726">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele was caused by This, which leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="727">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele will lead us to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="728">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, but not a wild-type strain, led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="729">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, in turn, has led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="730">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, in turn, is able to lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="731">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, in turn, is leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="732">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, in turn, leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="733">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, in turn, led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="734">
                    <text>a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele, in turn, will lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="REPLACE" no="735">
                    <text>a complex splice site mutation G:C base pair is also the strongest determinant in This leading to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="736">
                    <text>a complex splice site mutation G:C base pair is also the strongest determinant in This that leads to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="737">
                    <text>a complex splice site mutation G:C base pair is also the strongest determinant in This which has led to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="738">
                    <text>a complex splice site mutation G:C base pair is also the strongest determinant in This which leads to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="739">
                    <text>a complex splice site mutation G:C base pair is also the strongest determinant in This which led to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="740">
                    <text>a complex splice site mutation G:C base pair is also the strongest determinant in This, which led to an abnormal JAG1 mRNA, resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="741">
                    <text>a complex splice site mutation can lead to an abnormal JAG1 mRNA, resulting in a premature stop codon (Figure 3A).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="742">
                    <text>a complex splice site mutation can lead to an abnormal JAG1 mRNA, resulting in a premature stop codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="743">
                    <text>a complex splice site mutation can lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="744">
                    <text>a complex splice site mutation can lead us to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="745">
                    <text>a complex splice site mutation has led to an abnormal JAG1 mRNA, resulting in a premature stop codon (Figure 3A).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="746">
                    <text>a complex splice site mutation has led to an abnormal JAG1 mRNA, resulting in a premature stop codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="747">
                    <text>a complex splice site mutation has led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="748">
                    <text>a complex splice site mutation has led us to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="749">
                    <text>a complex splice site mutation is able to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon (Figure 3A).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="750">
                    <text>a complex splice site mutation is leading to an abnormal JAG1 mRNA, resulting in a premature stop codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="751">
                    <text>a complex splice site mutation is leading to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="752">
                    <text>a complex splice site mutation lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="753">
                    <text>a complex splice site mutation leads to an abnormal JAG1 mRNA, resulting in a premature stop codon (Figure 3A).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="754">
                    <text>a complex splice site mutation leads to an abnormal JAG1 mRNA, resulting in a premature stop codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="755">
                    <text>a complex splice site mutation leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="756">
                    <text>a complex splice site mutation leads us to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="757">
                    <text>a complex splice site mutation led to an abnormal JAG1 mRNA, resulting in a premature stop codon (Figure 3A).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="758">
                    <text>a complex splice site mutation led to an abnormal JAG1 mRNA, resulting in a premature stop codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="759">
                    <text>a complex splice site mutation led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="760">
                    <text>a complex splice site mutation led us to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="761">
                    <text>a complex splice site mutation may lead to an abnormal JAG1 mRNA, resulting in a premature stop codon (Figure 3A).</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="762">
                    <text>a complex splice site mutation may lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="763">
                    <text>a complex splice site mutation that leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="764">
                    <text>a complex splice site mutation was caused by This leading to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="765">
                    <text>a complex splice site mutation was caused by This that leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="766">
                    <text>a complex splice site mutation was caused by This that led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="767">
                    <text>a complex splice site mutation was caused by This which can lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="768">
                    <text>a complex splice site mutation was caused by This which has led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="769">
                    <text>a complex splice site mutation was caused by This, which leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="770">
                    <text>a complex splice site mutation will lead us to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="771">
                    <text>a complex splice site mutation, but not a wild-type strain, led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="772">
                    <text>a complex splice site mutation, in turn, has led to an abnormal JAG1 mRNA, resulting in a premature stop codon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="773">
                    <text>a complex splice site mutation, in turn, is able to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="774">
                    <text>a complex splice site mutation, in turn, is leading to an abnormal JAG1 mRNA, resulting in a premature stop codon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="775">
                    <text>a complex splice site mutation, in turn, leads to an abnormal JAG1 mRNA, resulting in a premature stop codon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="776">
                    <text>a complex splice site mutation, in turn, led to an abnormal JAG1 mRNA, resulting in a premature stop codon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="777">
                    <text>a complex splice site mutation, in turn, will lead to an abnormal JAG1 mRNA, resulting in a premature stop codon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="778">
                    <text>a point mutation at the 5 splicing site of the third intron G:C base pair is also the strongest determinant in This leading to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="779">
                    <text>a point mutation at the 5 splicing site of the third intron G:C base pair is also the strongest determinant in This that leads to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="780">
                    <text>a point mutation at the 5 splicing site of the third intron G:C base pair is also the strongest determinant in This which has led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="781">
                    <text>a point mutation at the 5 splicing site of the third intron G:C base pair is also the strongest determinant in This which leads to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="782">
                    <text>a point mutation at the 5 splicing site of the third intron G:C base pair is also the strongest determinant in This which led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="783">
                    <text>a point mutation at the 5 splicing site of the third intron G:C base pair is also the strongest determinant in This, which led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="784">
                    <text>a point mutation at the 5 splicing site of the third intron can lead to ligation of the second to the fourth exon (Figure 3A).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="785">
                    <text>a point mutation at the 5 splicing site of the third intron can lead to ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="786">
                    <text>a point mutation at the 5 splicing site of the third intron can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="787">
                    <text>a point mutation at the 5 splicing site of the third intron can lead us to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="788">
                    <text>a point mutation at the 5 splicing site of the third intron has led to ligation of the second to the fourth exon (Figure 3A).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="789">
                    <text>a point mutation at the 5 splicing site of the third intron has led to ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="790">
                    <text>a point mutation at the 5 splicing site of the third intron has led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="791">
                    <text>a point mutation at the 5 splicing site of the third intron has led us to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="792">
                    <text>a point mutation at the 5 splicing site of the third intron is able to lead to ligation of the second to the fourth exon (Figure 3A).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="793">
                    <text>a point mutation at the 5 splicing site of the third intron is leading to ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="794">
                    <text>a point mutation at the 5 splicing site of the third intron is leading to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="795">
                    <text>a point mutation at the 5 splicing site of the third intron lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="796">
                    <text>a point mutation at the 5 splicing site of the third intron leads to ligation of the second to the fourth exon (Figure 3A).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="797">
                    <text>a point mutation at the 5 splicing site of the third intron leads to ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="798">
                    <text>a point mutation at the 5 splicing site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="799">
                    <text>a point mutation at the 5 splicing site of the third intron leads us to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="800">
                    <text>a point mutation at the 5 splicing site of the third intron led to ligation of the second to the fourth exon (Figure 3A).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="801">
                    <text>a point mutation at the 5 splicing site of the third intron led to ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="802">
                    <text>a point mutation at the 5 splicing site of the third intron led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="803">
                    <text>a point mutation at the 5 splicing site of the third intron led us to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="804">
                    <text>a point mutation at the 5 splicing site of the third intron may lead to ligation of the second to the fourth exon (Figure 3A).</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="805">
                    <text>a point mutation at the 5 splicing site of the third intron may lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="806">
                    <text>a point mutation at the 5 splicing site of the third intron that leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="807">
                    <text>a point mutation at the 5 splicing site of the third intron was caused by This leading to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="808">
                    <text>a point mutation at the 5 splicing site of the third intron was caused by This that leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="809">
                    <text>a point mutation at the 5 splicing site of the third intron was caused by This that led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="810">
                    <text>a point mutation at the 5 splicing site of the third intron was caused by This which can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="811">
                    <text>a point mutation at the 5 splicing site of the third intron was caused by This which has led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="812">
                    <text>a point mutation at the 5 splicing site of the third intron was caused by This, which leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="813">
                    <text>a point mutation at the 5 splicing site of the third intron will lead us to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="814">
                    <text>a point mutation at the 5 splicing site of the third intron, but not a wild-type strain, led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="815">
                    <text>a point mutation at the 5 splicing site of the third intron, in turn, has led to ligation of the second to the fourth exon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="816">
                    <text>a point mutation at the 5 splicing site of the third intron, in turn, is able to lead to ligation of the second to the fourth exon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="817">
                    <text>a point mutation at the 5 splicing site of the third intron, in turn, is leading to ligation of the second to the fourth exon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="818">
                    <text>a point mutation at the 5 splicing site of the third intron, in turn, leads to ligation of the second to the fourth exon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="819">
                    <text>a point mutation at the 5 splicing site of the third intron, in turn, led to ligation of the second to the fourth exon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="820">
                    <text>a point mutation at the 5 splicing site of the third intron, in turn, will lead to ligation of the second to the fourth exon independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="821">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) is led to by G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="822">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) is led to by G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="823">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) was led to by G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14.</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="824">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) was led to by G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="825">
                    <text>a splicing defect in vivo, indicating that the protein is essential for splicing is led to by Disruption of the SNU246 gene in yeast.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="826">
                    <text>a splicing defect in vivo, indicating that the protein is essential for splicing was led to by Disruption of the SNU246 gene in yeast.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="827">
                    <text>abnormal splice in exon 5 and exon 6 is led to by The splice mutation in 5 end of intron 5.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="828">
                    <text>abnormal splice in exon 5 and exon 6 is led to by This splice mutation in 5 end of intron 5.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="829">
                    <text>abnormal splice in exon 5 and exon 6 was led to by The splice mutation in 5 end of intron 5.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="830">
                    <text>abnormal splice in exon 5 and exon 6 was led to by This splice mutation in 5 end of intron 5.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="831">
                    <text>an abnormal JAG1 mRNA, resulting in a premature stop codon is led to by a complex splice site mutation.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="832">
                    <text>an abnormal JAG1 mRNA, resulting in a premature stop codon was led to by a complex splice site mutation.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="833">
                    <text>cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 is led to by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="834">
                    <text>cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 was led to by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="835">
                    <text>derepression of treB is led to by The loss of TreR function.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="836">
                    <text>derepression of treB was led to by The loss of TreR function.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="837">
                    <text>inactivation of the MEF2C gene G:C base pair is also the strongest determinant in This leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="838">
                    <text>inactivation of the MEF2C gene G:C base pair is also the strongest determinant in This that leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="839">
                    <text>inactivation of the MEF2C gene G:C base pair is also the strongest determinant in This which has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="840">
                    <text>inactivation of the MEF2C gene G:C base pair is also the strongest determinant in This which leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="841">
                    <text>inactivation of the MEF2C gene G:C base pair is also the strongest determinant in This which led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="842">
                    <text>inactivation of the MEF2C gene G:C base pair is also the strongest determinant in This, which led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="843">
                    <text>inactivation of the MEF2C gene can lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="844">
                    <text>inactivation of the MEF2C gene can lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="845">
                    <text>inactivation of the MEF2C gene can lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="846">
                    <text>inactivation of the MEF2C gene can lead us to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="847">
                    <text>inactivation of the MEF2C gene has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="848">
                    <text>inactivation of the MEF2C gene has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="849">
                    <text>inactivation of the MEF2C gene has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="850">
                    <text>inactivation of the MEF2C gene has led us to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="851">
                    <text>inactivation of the MEF2C gene is able to lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="852">
                    <text>inactivation of the MEF2C gene is leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="853">
                    <text>inactivation of the MEF2C gene is leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="854">
                    <text>inactivation of the MEF2C gene lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="855">
                    <text>inactivation of the MEF2C gene leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="856">
                    <text>inactivation of the MEF2C gene leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="857">
                    <text>inactivation of the MEF2C gene leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="858">
                    <text>inactivation of the MEF2C gene leads us to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="859">
                    <text>inactivation of the MEF2C gene led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="860">
                    <text>inactivation of the MEF2C gene led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="861">
                    <text>inactivation of the MEF2C gene led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="862">
                    <text>inactivation of the MEF2C gene led us to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="863">
                    <text>inactivation of the MEF2C gene may lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="864">
                    <text>inactivation of the MEF2C gene may lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="865">
                    <text>inactivation of the MEF2C gene that leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="866">
                    <text>inactivation of the MEF2C gene was caused by This leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="867">
                    <text>inactivation of the MEF2C gene was caused by This that leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="868">
                    <text>inactivation of the MEF2C gene was caused by This that led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="869">
                    <text>inactivation of the MEF2C gene was caused by This which can lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="870">
                    <text>inactivation of the MEF2C gene was caused by This which has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="871">
                    <text>inactivation of the MEF2C gene was caused by This, which leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="872">
                    <text>inactivation of the MEF2C gene will lead us to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="873">
                    <text>inactivation of the MEF2C gene, but not a wild-type strain, led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="874">
                    <text>inactivation of the MEF2C gene, in turn, has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="875">
                    <text>inactivation of the MEF2C gene, in turn, is able to lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="876">
                    <text>inactivation of the MEF2C gene, in turn, is leading to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="877">
                    <text>inactivation of the MEF2C gene, in turn, leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="878">
                    <text>inactivation of the MEF2C gene, in turn, led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="879">
                    <text>inactivation of the MEF2C gene, in turn, will lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="880">
                    <text>ligation of the second to the fourth exon is led to by a point mutation at the 5 splicing site of the third intron.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="881">
                    <text>ligation of the second to the fourth exon was led to by a point mutation at the 5 splicing site of the third intron.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="882">
                    <text>the distinct amino termini G:C base pair is also the strongest determinant in This leading to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="883">
                    <text>the distinct amino termini G:C base pair is also the strongest determinant in This that leads to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="884">
                    <text>the distinct amino termini G:C base pair is also the strongest determinant in This which has led to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="885">
                    <text>the distinct amino termini G:C base pair is also the strongest determinant in This which leads to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="886">
                    <text>the distinct amino termini G:C base pair is also the strongest determinant in This which led to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="887">
                    <text>the distinct amino termini G:C base pair is also the strongest determinant in This, which led to the targeting of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="888">
                    <text>the distinct amino termini can lead to the targeting of individual VDAC isoforms to different cellular compartments (Figure 3A).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="889">
                    <text>the distinct amino termini can lead to the targeting of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="890">
                    <text>the distinct amino termini can lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="891">
                    <text>the distinct amino termini can lead us to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="892">
                    <text>the distinct amino termini has led to the targeting of individual VDAC isoforms to different cellular compartments (Figure 3A).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="893">
                    <text>the distinct amino termini has led to the targeting of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="894">
                    <text>the distinct amino termini has led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="895">
                    <text>the distinct amino termini has led us to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="896">
                    <text>the distinct amino termini is able to lead to the targeting of individual VDAC isoforms to different cellular compartments (Figure 3A).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="897">
                    <text>the distinct amino termini is leading to the targeting of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="898">
                    <text>the distinct amino termini is leading to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="899">
                    <text>the distinct amino termini lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="900">
                    <text>the distinct amino termini leads to the targeting of individual VDAC isoforms to different cellular compartments (Figure 3A).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="901">
                    <text>the distinct amino termini leads to the targeting of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="902">
                    <text>the distinct amino termini leads to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="903">
                    <text>the distinct amino termini leads us to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="904">
                    <text>the distinct amino termini led to the targeting of individual VDAC isoforms to different cellular compartments (Figure 3A).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="905">
                    <text>the distinct amino termini led to the targeting of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="906">
                    <text>the distinct amino termini led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="907">
                    <text>the distinct amino termini led us to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="908">
                    <text>the distinct amino termini may lead to the targeting of individual VDAC isoforms to different cellular compartments (Figure 3A).</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="909">
                    <text>the distinct amino termini may lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="910">
                    <text>the distinct amino termini that leads to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="911">
                    <text>the distinct amino termini was caused by This leading to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="912">
                    <text>the distinct amino termini was caused by This that leads to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="913">
                    <text>the distinct amino termini was caused by This that led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="914">
                    <text>the distinct amino termini was caused by This which can lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="915">
                    <text>the distinct amino termini was caused by This which has led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="916">
                    <text>the distinct amino termini was caused by This, which leads to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="917">
                    <text>the distinct amino termini will lead us to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="918">
                    <text>the distinct amino termini, but not a wild-type strain, led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="919">
                    <text>the distinct amino termini, in turn, has led to the targeting of individual VDAC isoforms to different cellular compartments independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="920">
                    <text>the distinct amino termini, in turn, is able to lead to the targeting of individual VDAC isoforms to different cellular compartments independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="921">
                    <text>the distinct amino termini, in turn, is leading to the targeting of individual VDAC isoforms to different cellular compartments independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="922">
                    <text>the distinct amino termini, in turn, leads to the targeting of individual VDAC isoforms to different cellular compartments independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="923">
                    <text>the distinct amino termini, in turn, led to the targeting of individual VDAC isoforms to different cellular compartments independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="924">
                    <text>the distinct amino termini, in turn, will lead to the targeting of individual VDAC isoforms to different cellular compartments independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="925">
                    <text>the targeting of individual VDAC isoforms to different cellular compartments is led to by the distinct amino termini.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="926">
                    <text>the targeting of individual VDAC isoforms to different cellular compartments was led to by the distinct amino termini.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="927">
                    <text>truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations is led to by two frameshifts and a splice site mutation.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="928">
                    <text>truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations was led to by two frameshifts and a splice site mutation.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="929">
                    <text>two frameshifts and a splice site mutation G:C base pair is also the strongest determinant in This leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="930">
                    <text>two frameshifts and a splice site mutation G:C base pair is also the strongest determinant in This that leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="931">
                    <text>two frameshifts and a splice site mutation G:C base pair is also the strongest determinant in This which has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="932">
                    <text>two frameshifts and a splice site mutation G:C base pair is also the strongest determinant in This which leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="933">
                    <text>two frameshifts and a splice site mutation G:C base pair is also the strongest determinant in This which led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="934">
                    <text>two frameshifts and a splice site mutation G:C base pair is also the strongest determinant in This, which led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="935">
                    <text>two frameshifts and a splice site mutation can lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Figure 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="936">
                    <text>two frameshifts and a splice site mutation can lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="937">
                    <text>two frameshifts and a splice site mutation can lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="938">
                    <text>two frameshifts and a splice site mutation can lead us to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="939">
                    <text>two frameshifts and a splice site mutation has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Figure 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="940">
                    <text>two frameshifts and a splice site mutation has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="941">
                    <text>two frameshifts and a splice site mutation has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="942">
                    <text>two frameshifts and a splice site mutation has led us to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="943">
                    <text>two frameshifts and a splice site mutation is able to lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Figure 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="944">
                    <text>two frameshifts and a splice site mutation is leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="945">
                    <text>two frameshifts and a splice site mutation is leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="946">
                    <text>two frameshifts and a splice site mutation lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="947">
                    <text>two frameshifts and a splice site mutation leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Figure 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="948">
                    <text>two frameshifts and a splice site mutation leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="949">
                    <text>two frameshifts and a splice site mutation leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="950">
                    <text>two frameshifts and a splice site mutation leads us to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="951">
                    <text>two frameshifts and a splice site mutation led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Figure 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="952">
                    <text>two frameshifts and a splice site mutation led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="953">
                    <text>two frameshifts and a splice site mutation led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="954">
                    <text>two frameshifts and a splice site mutation led us to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="955">
                    <text>two frameshifts and a splice site mutation may lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations (Figure 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="956">
                    <text>two frameshifts and a splice site mutation may lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="957">
                    <text>two frameshifts and a splice site mutation that leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="958">
                    <text>two frameshifts and a splice site mutation was caused by This leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="959">
                    <text>two frameshifts and a splice site mutation was caused by This that leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="960">
                    <text>two frameshifts and a splice site mutation was caused by This that led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="961">
                    <text>two frameshifts and a splice site mutation was caused by This which can lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="962">
                    <text>two frameshifts and a splice site mutation was caused by This which has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="963">
                    <text>two frameshifts and a splice site mutation was caused by This, which leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="964">
                    <text>two frameshifts and a splice site mutation will lead us to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="965">
                    <text>two frameshifts and a splice site mutation, but not a wild-type strain, led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="966">
                    <text>two frameshifts and a splice site mutation, in turn, has led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="967">
                    <text>two frameshifts and a splice site mutation, in turn, is able to lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="968">
                    <text>two frameshifts and a splice site mutation, in turn, is leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="969">
                    <text>two frameshifts and a splice site mutation, in turn, leads to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="970">
                    <text>two frameshifts and a splice site mutation, in turn, led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="REPLACE" no="971">
                    <text>two frameshifts and a splice site mutation, in turn, will lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
